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Endogenously recruited myelin oligodendrocyte glycoprotein (MOG)-binding B cells have been 
observed in relapsing remitting (RR) experimental autoimmune encephalomyelitis (EAE) mice 
where all T cells are transgenic and specific for MOG 92-106 peptide. The aim of this study was to 
characterize MOG-binding B cells and preclinical events in RR mice.  
 
Recombinant fluorescent MOG tetramers were utilized to find MOG-binding B cells which 
occurred at low frequency in RR mice. MOG-binding B cells were distributed throughout the 
immune compartments, with a tendency to accumulate in the cervical lymph nodes, which drain 
the central nervous system (CNS). MOG-binding B cells were mature; isotype switched and 
preferentially resided within the germinal center (GC). Analysis of affinity purified serum anti-
MOG antibodies suggested a heterogeneous population of endogenous MOG-specific B cells in 
RR mice. Anti-MOG antibodies were found in the serum of encephalitic, and also of healthy RR 
mice. There is a strong correlation between the number of CNS infiltrating T and B cells and 





In dieser Doktorarbeit wurde ein Tiermodell bearbeitet, in dem spontan eine schubförmig-
remittierende experimentelle autoimmune Enzephalomyelitis Enzephalitis auftritt (RR-Maus). In 
dieser RR-Maus sind alle T-Zellen transgen und spezifisch für MOG. Ziel dieser Studie war es, 
MOG-bindende B-Zellen und Abläufe vor Beginn der Erkrankung in RR-Mäusen zu 
charakterisieren.  
 
Um MOG-bindende B-Zellen zu finden, die in niedriger Frequenz bei RR-Mäusen auftreten, 
wurden rekombinante fluoreszierende MOG Tetramere eingesetzt. MOG-bindende B-Zellen 
waren innerhalb der immunen Kompartimente verteilt, mit einer Tendenz zur Ansammlung in 
Halslymphknoten, die das zentrale Nervensystem (ZNS) drainieren. MOG-bindende B-Zellen 
waren ausgereift, Isotop-gewechselt und vorzugsweise innerhalb der Keimzentren lokalisiert. 
Die Aufreinigung von Serum anti-MOG-Antikörpern zeigte einen heterogenen Bestand von 
endogenen MOG-spezifischen B-Zellen. Anti-MOG-Antikörper zirkulierten sowohl im Serum 
enzephalitischer als auch gesunder RR Mäuse. Es gab eine starke Korrelation zwischen der 
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1.  Introduction 
1.1  Multiple sclerosis (MS) 
The central nervous system (CNS) which includes the brain, spinal cord and optic nerves is a 
structurally and functionally unique, immunologically privileged organ (Lassmann et al., 1998). It 
has been shown that the effective immune surveillance mechanisms are necessary to protect 
CNS against injurious agents. However, failure to control unwanted auto reactive immune 
responses in the CNS can result in chronic immunopathological disorders, such as multiple 
sclerosis (MS) and neuromyelitis optica (NMO) (Lassmann et al., 1998). MS is a chronic 
autoimmune demyelinating disease of CNS that affects primarily young people (Weinshenker, 
1998). The prevalence of MS is about 2.5 million, worldwide (Weinshenker, 1998). MS leads to 
disability at the level of physiological and cognitive functions with symptoms being primarily 
depended on the location and the spread of demyelinated CNS areas. Symptoms can be quite 
diverse ranging from sensibility disorders, fatigue, dizziness, deterioration of vision, up to 
paralysis (Compston and Coles). The majority of patients develop MS with a relapsing remitting 
(RR) clinical course, with alternating periods of acute disease and recovery (Compston and 
Coles). After an initial phase, patients can recover completely and remain free of symptoms until 
the disease reinitiates. Relapses can last for days or weeks with varying recoveries. Over time, 
patients with RR MS may develop secondary-progressive MS, which often leads to severe 
disability. A minority of patients, though, suffers from primary-progressive MS, a rather 
aggressive form of the disease developing gradually but steadily from the very beginning. MS is 
mainly believed to be mediated by immune cells that attack myelin sheath produced by 
oligodendrocytes which leads to axonal damage and ultimately, to neuronal death (Engelhardt 
and Coisne, 2011).  
The etiology of MS is dictated by both genetic and environmental factors (Compston and Coles). 
One important genetic risk factor is major histocompatibility complex (MHC), human leukocyte 
antigen (HLA) class II (Hafler et al., 2007). MHC II is vital for CD4+ T lymphocytes activation by 
antigen-presenting cells (APC). In addition, genome wide association studies (GWAS) identified 
numerous immune-related genes, including the cytokine receptors for interleukin (IL)-2 and IL-7, 
as risk factors supporting the autoimmune pathogenesis of the MS (Fugger et al., 2009). 
Environmental influences on MS pathogenesis were suggested by the geographical differences 
in the occurrence of MS. Northern European and Northern American countries show a higher 
incidence of MS than regions closer to the equator (Kurtzke, 1993). This might be partly 
explained by the reduced sun exposure hence vitamin D, leading to a higher probability of 
developing MS (Smolders et al., 2008). It was also proposed that bacteria such as β-hemolytic 
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streptococcus or viral infections, like the Epstein-Barr virus (Vartdal et al., 1980), could trigger 
MS by means of molecular mimicry or through bystander activation of the immune system, but 
so far none has been proven, unequivocally (Lünemann and Münz, 2009). 
 
1.2  Experimental animal models of MS  
There are three main experimental demyelination models available to study the MS 
pathogenesis; these are toxic, viral, and immune mediated. The toxic models of MS include the 
use of cuprizone (Blakemore, 1973), ethidium bromide (Blakemore and Franklin, 2008), and 
lysophosphatidylcholine (Low et al., 1983). In the cuprizone model, mice are fed with the copper 
chelator, cuprizone (2% in chow) for 4–6 weeks. Cuprizone treatment causes mitochondrial 
dysfunction in oligodendrocytes leading to apoptosis (Matsushima and Morell, 2001). 
Interestingly, after cessation of cuprizone treatment remyelination ensues thus, making this 
model useful to study oligodendrocytes cell death, as well as, for examining mechanisms of 
remyelination. The second toxic model is the microinjection of lysophosphatidylcholine or 
ethidium bromide into white matter tracts causing rapid demyelination, followed by remyelination 
(Blakemore and Franklin, 2008). Similar to the cuprizone model, these two toxic models have 
been used to examine cellular and molecular determinants of remyelination (Blakemore and 
Franklin, 2008). The pitfall of all toxic models is the absence of ongoing immune activity. 
The second experimental demyelination model is the viral model of MS. This model relies on the 
experimental infection of rodents with Theiler's murine encephalomyelitis virus (TMEV), mouse 
hepatitis virus (MHV), and Semliki forest virus (SFV), which eventually induces demyelination in 
the CNS. The best-studied viral demyelination models are TMEV and MHV (McCarthy et al., 
2012). Viral models of MS provided insight into mechanisms by which autoimmunity are 
established (Miller et al., 1997) and some behavioral signs following demyelination of the murine 
CNS (Rivera-Quinones et al., 1998). However, the downside of this model is that viral-induced 
demyelination probably differs from that of MS, where persistent viral infection of the CNS has 
not been demonstrated. 
The third, myelin antigen induced animal model, involves an immune mediated demyelination. 
This model is widely used in experimental studies and is being discussed in extensive detail in 
the following section as studies conducted during this research focuses on immunopathogensis 






1.2.1  Experimental autoinmune encephalitis/encephalomyelitis (EAE)  
EAE is one of the most frequently studied MS animal models. EAE is induced in susceptible 
mouse strains by active immunization with complete Freund’s adjuvant and pertussis toxin 
together with antigen of interest (McCarthy et al., 2012). Several antigen preparations have 
been used to induce EAE including whole CNS tissue (Wekerle et al., 1994b), purified myelin 
(Wekerle et al., 1994a) myelin proteins or peptides from myelin antigens such as myelin 
oligodendrocytes glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP) 
(Bradl and Linington, 1996). The incubation period between immunization, and disease onset, 
and the severity of clinical symptoms depends on the genetics (species and strain) of animals 
and experimental factors. Experimental factors includes mode of immunization, dose and nature 
of injected antigen (Krishnamoorthy and Wekerle, 2009). Unfortunately, the necessity of 
adjuvant and pertussis toxin for the induction of active EAE limits the applicability of this model, 
especially during the initial stages of autoimmune disease processes. These limitations are 
bypassed when EAE is induced by transfer of pre-activated lymphocytes isolated from 
immunized donor mice which are reactivated in vitro with myelin antigen (Paterson, 1960). 
Passive EAE develops faster and more homogeneously than active EAE, it avoids CFA 
inoculation, allows the manipulation of pathogenic T cells ex vivo, and facilitates the analysis of 
effector functions of transferred T cells (Ben-Nun et al., 1981). Nevertheless, it does not 
facilitate the study of the initial steps of the induction of the disease therefore; a spontaneous 
EAE model is essential. 
 
1.2.2  Spontaneous EAE animal models 
Spontaneous CNS autoimmunity can be initiated by neurodegenerative disease, genetic 
manipulation of inflammatory mediators or T and B cell receptors. Spontaneous EAE models 
were extensively reviewed by Krishnamoorthy et al. (2007), and they concluded that certain 
neurodegenerative diseases exhibit EAE-like demyelinating lesions within CNS. One animal 
model of neurodegenerative disease is Twitcher mouse (Suzuki and Suzuki, 1995). Twitcher 
mouse is a naturally occurring model of Krabbe disease resulting in dysfunctional metabolism of 
sphingolipids, one of the vital components of myelin sheath (Suzuki and Suzuki, 1995). Myelin 
degeneration in Twitcher mice leads to immune cell infiltrates to the CNS (Ohno et al., 1993). In 
addition, selective expression of specific cytokines/chemokines in the CNS tissue, such as 
tumor necrosis factor alpha (TNF)-α, interferon gamma IFN-γ, IL-6, IL-12 (both p35 and p40), 
chemokine CC motif ligand (CCL)-21 and CCL-2, might lead in some cases to increased 
proinflammatory milieu within the CNS and increased immune cell infiltration (Krishnamoorthy et 
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al., 2007). And increased immune cells infiltration results in a neurological syndrome that 
resembles, at least in part T-cell mediated EAE yet they do not fully replicate the major features 
of MS pathology.  
 
The introduction of myelin antigen-specific T cell receptors (TCR) and B cell receptors (BCR) in 
transgenic mice overcame aforementioned limitations. These models developed EAE disease 
without the need of the antigen/CFA immunization. Like any other autoimmune disease 
spontaneous EAE is determined by intrinsic factors like the genetic background of the mice, 










Lesions character and location 
19 MBP Ac1–9 PL/J or B10.PL (I-
Au) 
100% in RAG 
deficient 
background 
Mononuclear cell infiltrates in the brain and 
spinal cord (Lafaille et al., 1994) 
172.10 MBP Ac1–11 B10.PL (I-Au) 14–44% Macrophage and lymphocyte infiltration in 
the spinal cord white matter (Goverman et 
al., 1993) 
5B6 PLP 139–151 SJL.J (I-As) 60–83% Inflammatory foci in the CNS (Waldner et 
al., 2000) 
4E3 PLP 139–151 SJL.J (I-As) 45% Inflammatory foci in the CNS (Waldner et 
al., 2000) 
2D2 MOG 35–55 C57BL/6 (I-Ab) 4% EAE and 30% 
optic neuritis 
Optic neuritis, and mononuclear cell 
infiltrates in meninges and CNS 
parenchyma (Bettelli et al., 2003) 
TCR1640  MOG 92-106 SJL.J (I-As) 80% spontaneous 
EAE 
T and B-lymphocytes infiltrates in the brain 
and spinal cord. Prominent deposits of 
Immunoglobulin and some activated 






C57BL/6 (I-Ab) 50% opticospinal 
(OSE) EAE 
Inflammatory and demyelinating lesions in 
the optic nerve and in the spinal cord 
(Krishnamoorthy et al., 2006) 
Ob.1A12 hMBP 84–102 Humanized Tg 
(HLA-DR2) 





Inflammatory and demyelinating lesions 
throughout the CNS and composed of 
neutrophilic granulocytes, activated 
macrophages and T lymphocytes (Madsen 
et al., 1999) 




conditions. Those intrinsic and environmental factors have a great influence on spontaneous 
diseases.  
Examples of CD4+ T cell receptors transgenic mice recognizing different myelin antigen 
epitopes in the context of MHC class II determinants the development of spontaneous EAE 
during its adult life with different frequencies, histological and clinical courses as summarized in 
(Table 1.1) (Krishnamoorthy et al., 2007). Briefly, as seen in Table (1.1) MBP-transgenic mice 
develop spontaneous EAE when bred on a recombination-activating gene (RAG)-knockout (KO) 
background, in non-sterile housing conditions (Goverman et al., 1993). This effect was 
attributed to the absence of MBP-specific T regulatory (Treg) cells that control autoreactive T 
cells and passive transfer of wild type CD4+ CD25+ T cells prevented spontaneous EAE 
(Olivares-Villagómez et al., 1998). MOG35-55 peptide-reactive TCR transgenic mice, 2D2, 
develop spontaneous optic neuritis without any clinical or histological sign of EAE (Bettelli et al., 
2003). However, they develop EAE when immunized with MOG or by injection of pertussis 
toxin. The clinical differences between EAE models can be attributed to both non-MHC 
background genes (Storch et al., 1998) and different target antigens which might induce 
different types of immunopathology (Sobel, 2000). Further improvements by the introduction of 
MOG-specific B cell receptor transgenes along with 2D2; TCR double-transgenic 2D2 x IgHMOG; 
termed opticospinal EAE (OSE) mice, led to the development of spontaneous EAE at an 
incidence of about 50% (Krishnamoorthy et al., 2006, Bettelli et al., 2006). OSE mice 
spontaneously develop an inflammatory demyelinating disease affecting the spinal cord and 
optic nerves but spares the brain stem and cerebellum, similar to human opticospinal MS or 
Devic’s disease (Krishnamoorthy et al., 2006, Bettelli et al., 2006). Spontaneous EAE in OSE 
mice is a result of a pathogenic interaction between MOG-specific T and B cells where MOG-
specific B cells concentrate and present recombinant MOG to T cells and, T cells induce the B 
cells to switch immunoglobulin production from IgM to IgG isotypes (Krishnamoorthy et al., 
2007).  
While table (1.1) only presents transgenic mice with autoreactive myelin-specific CD4+ T cells, 
there are also few of myelin-specific CD8+ T cell transgenic mice, which, failed to develop 
spontaneous EAE (Huseby et al., 1999, Perchellet et al., 2004). Failure to develop spontaneous 
EAE by autoreactive myelin-specific CD8+ might be explained by their suppressive and 
regulatory role in EAE seen in several studies. One example is, when CD8+ T cells isolated from 
EAE-recovered mice and cultured with MBP-activated CD4+ T cell clones inhibited their activity 
in vitro and prevented disease in the recipients after transfer of those cultured MBP-activated 
CD4+ T cell clones to MBP-immunized mice (Jiang et al., 2003). 
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Finally, the last example of spontaneous EAE animal models are “humanized” transgenic mice, 
which harbor TCRs that were cloned from human CD4+ T cells (clone Ob.1A12), recognize 
MBP84-102 peptide in the context of an MS-susceptible human MHC class II protein, DR15 
(Madsen et al., 1999). Spontaneous EAE incidence in these humanized mice was less than 5% 
but increased when crossed with RAG knockout mice. Another strain of mice carry humanized 
TCR, which recognize MBP85-99 peptide had a EAE frequency of 60%, with more severe clinical 
deficiencies (Ellmerich et al., 2005).  
 
1.2.3  The relapsing remitting (RR) mice animal model 
Relapsing remitting (RR) mice are transgenic mice expressing a T cell receptor (TCR) specific 
for the MOG peptide 92–106 (MOG92-106) in the context of I-As MHC class II. This TCR, 
consisting of Vα8.3 and Vβ4 genes, was derived from a MOG-specific encephalitogenic Th1-
CD4+ T cell clone isolated from a WT SJL/J mouse immunized against recombinant MOG 
(Pollinger et al., 2009). These mice, are kept under specific pathogen free (SPF) conditions, 
usually develop spontaneous RR diseases at an age older than 8 weeks, with an EAE incidence 
of over 80% (Pollinger et al., 2009).  
Most importantly, these T cells recruit endogenous MOG-specific B cells around the age of 3 
weeks (Pollinger et al., 2009). Transgenic RR mice produce high titers of anti-MOG 
autoantibodies with IgG1 and IgG2 isotypes. These endogenous B cells were present in the 
inflammatory lesions of the CNS. There were also local deposits of immunoglobulin (Ig) along 
with some activated complement in the CNS (Pollinger et al., 2009).  
B cells have an essential role in the spontaneous development of RR-EAE (Pollinger et al., 
2009). B cells can contribute to autoimmune responses via secreting humoral antibodies, acting 
as antigen presenting cells (APCs), releasing cytokines and interacting with autoimmune T cells. 
In RR-EAE, the humoral response seems to be vital. B cell depletion, using anti-CD20 
monoclonal antibodies (mAb) during the neonatal period of the mice life, suppressed RR-EAE, 
while depletion of B cells in adult mice results in accelerated clinical courses (Pollinger et al., 
2009). In addition, MOG-specific B cell expansion critically requires the presence of the 
endogenous target autoantigen, as MOG-KO RR SJL/J mice never produced anti-MOG 
autoantibodies (Pollinger et al., 2009).  
 
1.3  Immunopathology in MS and EAE 
MS and EAE are immune-mediated diseases of the CNS characterized by initial inflammation, 
followed by demyelination, and finally axon loss (Lassmann et al., 1998). This initial 
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inflammation can lead to direct or indirect damage of myelin creating a pro-inflammatory milieu 
that stimulates drainage and/or transportation of neural autoantigen to the nearest CNS draining 
lymph nodes (Weller et al., 2009). Neural antigens are taken up by the APCs in the peripheral 
lymphoid tissue and presented to immune cells in order to stimulate and activate these cells. 
After activation, T and B cells with improved specificity for selective antigen expand. After clonal 
expansion, T and B cells infiltrate back to the CNS, and re-encounter their specific antigen. 
CD4+ T cells recognize their antigens presented by microglial cells on MHC class II molecules. 
B cells mature to plasma cells and release large amounts of antibodies that bind to soluble or 
membrane-bound antigens on expressing cells. Finally, reactivation of these cells leads to 
heightened production of inflammatory cytokines (Chabas et al., 2001). These cytokines attract 
other immune cells, such as macrophages, which contribute to inflammation through the release 
of injurious immune mediators and direct phagocytic attack on the myelin sheath (Figure.1.1).  
1.3.1  Neural antigen drainage 
The CNS has long been recognized as an ‘immune privilege' site because of the lack of 
lymphatic vessel drainage and the tight blood brain barrier (BBB) which reduce immune 
surveillance in the CNS (Abbott et al., 2010). Yet, adaptive immune responses can be initiated 
Figure 1.1. Schematic diagram of immune-pathogenesis in MS and EAE. (Adopted from Nature 
Reviews Neuroscience (Hemmer et al., 2002)) 
 
Lymphoid organs 
Central nervous system (CNS) 
CD8 T Cells 
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against CNS antigens, so immune privilege notion of CNS is not absolute (Wekerle, 2006). In 
fact, CNS is believed to possess a soluble route for antigen drainage to the lymphatic system 
via the interstitial fluid (ISF) and cerebrospinal fluid (CSF).  
ISF is the tissue fluid, which surrounds cells in any given organ. ISF is formed by hydrostatic 
pressure that pushes water and solutes from small blood vessels to extracellular space and 
eventually returns to blood via osmotic pressure through blood vascular walls (Weller, 1998). 
ISF and solutes are believed to travel in reverse manner to blood direction along the basement 
membrane of arteries between smooth muscle cells in the tunica media (Carare et al., 2008). 
Injections of different sized fluorescent tracers or labeled antigens in the CNS have revealed 
that ISF drains within 5 minutes to the basement membrane of blood vessel and diffuses in 
brain parenchyma (Carare et al., 2008). And after 30 minutes, fluorescent tracers were no 
longer present in vascular basement or brain parenchyma indicating there is an active ISF 
drainage in the CNS (Carare et al., 2008). In a similar study by (Szentistvanyi et al., 1984), 
radioactive tracers injected into the CNS were found in deep cervical lymph nodes and were 
believed to take a route other than the CSF draining route. The radioactive tracers were found in 
cranial arteries, which reside at the base of the skull but they were not found in the carotid artery 
in the neck. Cranial arteries are one of the CSF draining routes but ISF drainage is not merely 
separated from CSF drainage. After selective injection of trypan blue in the CSF, traces were 
found in perivascular macrophages that reside along the walls of arteries and capillaries, a route 
which is taken by ISF (Weller et al., 2009).  
CSF is produced by choroid plexus epithelial cells and small percentage of CSF comes from 
ISF. CSF flows from the ventricles into the subarachnoid space and circulate around the brain 
and spinal cord (Ransohoff and Engelhardt, 2012). There are two routes for lymphatic drainage 
of CSF. In the first route, CSF is directly drained via arachnoid villi to the blood and/or adsorbed 
into blood capillaries in the brain parenchyma (Weller et al., 2009). However, it appears that this 
route is important only under certain conditions such as elevated CSF pressure (Johnston et al., 
2004). Therefore, drainage of CSF from CNS across the cribriform plate along olfactory rootlets 
to the nasal mucosa and then to the different lymphatics of the deep cervical lymph nodes is 
regarded as the primary extracranial route (Johnston et al., 2005a). Johnston and his 
colleagues have injected a silicone rubber compound into subarachnoid spaces in both primates 
and non-primates and found that the material penetrated the cribriform plate above the nasal 
cavity. This route also has been proven with other studies like the one where India ink was 
injected into subarachnoid space and particles of India ink were observed in the perineurial 
space of the olfactory nerves and they penetrated the cribriform plate (Johnston et al., 2005b). 
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The lymphatic vessels in the nasopharyngeal mucosa were consequently filled with India ink 
tracer (Yoffey and Drinker, 1939). Furthermore, infused X-ray contrast medium into the cisterna 
magna of monkeys revealed that the contrast agent appeared to travel alongside the optic and 
olfactory nerves to nasal region to reside in the deep cervical lymph nodes reviewed in (Koh et 
al., 2005).  
As stated earlier, the partial immune surveillance of the CNS is believed to be facilitated by the 
transport of neural antigens via the lymphatic drainage of ISF and CSF to the CNS draining 
lymph nodes (Carare et al., 2008, Weller et al., 2009). ISF of the CNS drains via perivascular 
channels that are populated by perivascular macrophages and other APCs able to sample the 
full range of CNS antigens. Furthermore, the choroid plexus, cerebral ventricles and meninges 
contain cells that phenotypically resemble DCs and might potentially be capable of traveling to 
DCLNs (Bulloch et al., 2008). During CNS inflammation, APCs can be found within the brain 
demyelinating lesions. In fact, active demyelination is defined by the presence of phagocytic 
macrophages containing myelin protein inclusions. Additionally, some macrophages that 
expressed CC-chemokine receptor 7 (CCR7), indicating the capability to enter lymph nodes and 
potentially to present myelin antigens to T cells (Ransohoff and Engelhardt, 2012). However, 
there is no concrete evidence to support the possibility that APCs migrate from the CNS to the 
lymphatic system or vice versa. 
 
1.3.2  Cellular components of CNS in health and disease 
CNS is a unique organ in terms of function and structure, yet like any organ it requires effective 
immune mechanisms for protection against infection, despite its perception as a site of immune 
privilege (Wekerle, 2006). The effective immune surveillance is facilitated by the local innate 
APCs and infiltrating immune cells. Apart from T and B cells there is no other type of immune 
cells that have been extensively documented in a healthy CNS. 
 
APC population in the CNS 
The healthy CNS is populated, apart from myelin forming oligodendrocytes, with two main types 
of glial cells, microglia and astrocytes; they serve as innate sensors of the CNS. Innate APCs or 
myeloid cells of the CNS can be divided into two main populations (Ransohoff and Cardona, 
2010). The first population consists of parenchymal microglial cells, a highly specialized tissue-
specific macrophage. Second population consists of epiplexus cells of the choroid plexus and 
meningeal, perivascular and ventricular macrophages. Microglia develops early in life and 
maintained throughout the life by local proliferation. Systemic inflammation, stroke, physical 
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trauma and neurodegeneration lead to microglia activation (Ransohoff and Brown, 2012). The 
net results of microglial activation can be either beneficial or deleterious. In fact, neurons 
constitutively express cell-surface and secreted microglial inhibitors. Consequently, it is likely 
that neuronal cell death or injury converts the immunosuppressive environment to an 
inflammatory milieu (Ransohoff and Perry, 2009). Under such inflammatory conditions, CNS 
myeloid cells can upregulate APC- and DC-associated markers including CD11c, MHC class II 
and other co-stimulatory molecules (McMahon et al., 2006). CSF also contains a small 
proportion of monocytes which constitute ~5% of all CSF cells (Trebst et al., 2001). 
Astrocytes are best described as neuroglia cells. The main function of astrocytes includes 
buffering potassium, balancing water, and modulating synaptic activity (Sriram, 2011). 
Astrocytes also produce neurotrophins, inflammatory mediators and many chemokines (Sriram, 
2011). However, constant astrocytic stimulation during chronic inflammation has detrimental 
consequences as seen by microglial-astrocyte interactions in inflammatory conditions (Vesce et 
al., 2007, Bezzi et al., 2001). Chemokine C-X-C motif ligand (CXCL)-12 signals to astrocytes to 
promote physiological release of glutamate during synaptic transmission and to release small 
amounts of TNF-α. In inflammatory conditions, CXCL12 plus TNF-α from astrocytes and pro-
inflammatory conditions signal to microglia to produce large quantities of TNF-α which impairs 
the capacity of astrocytes to detoxify glutamate, resulting in neuronal loss (Vesce et al., 2007, 
Bezzi et al., 2001). In addition, astrocytes like microglia in an inflammatory condition can act as 
APC. Rat astrocytes upregulate MHC class II molecules after treatment with IFN-γ as a results 
gain the capacity to prime autoreactive T cells, and contribute to increased immune reactivity 
against nervous tissue (Fontana et al., 1984, Wekerle et al., 1987). 
T cells in the CNS 
In the late 1980s, it was shown that migration of T cells to CNS occurs even during non-
inflammatory conditions (Wekerle et al., 1986, Hickey, 1991). Tracing radioactively labeled 
encephalitogenic T cell blasts following their intravenous injection into Lewis rats suggested that 
resting lymphocytes fail to enter the CNS (Wekerle et al., 1986). The activation stage of T cells, 
rather than the antigen-specificity determines blood brain barrier (BBB) crossing in this model 
and enter the CNS (Hickey, 1991). After a few hours, however, neuroantigen specificity is 
needed for lymphoblast persistence in the CNS (Cross et al., 1990). 
Under normal physiological conditions, the majority of the immune cells enter the CNS barriers 
are confined to the perivascular and subarachnoid spaces filled with CSF, leaving the CNS 
parenchyma largely untouched (Giunti et al., 2003). The CSF of healthy individuals contains 
1,000–3,000 cells per ml, with ≥90% of the cells being T cells (Giunti et al., 2003). Those T cells 
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are mainly CD4+ memory T cells that have characteristics of both central memory T (TCM) cells 
and effector memory T (TEM) cells (Sallusto et al., 1999). These cells are furthermore, 
comparable with the corresponding CD4+ memory T cell populations in the blood (Kivisakk et 
al., 2006). It appears that T cells enter the CSF mainly across the choroid plexus in healthy 
individuals and early in neuroinflammatory disease (Ransohoff et al., 2003). They perform 
routine immunosurveillance of the CNS, by searching within the CSF-filled subarachnoid spaces 
for antigens presented by the rich network of subarachnoid-space macrophages (McMenamin, 
1999).  
 
1.3.3  Role of lymphocytes in MS and EAE 
1.3.3.1  T lymphocytes in MS and EAE 
The most important cellular drivers of MS pathogenesis seem to be T cells, presumably CD8+ 
cytotoxic T cells. In contrast, in most models of active EAE, myelin-specific CD4+ rather than 
CD8+ T cells are the central factor of autoimmune pathogenesis. This may be due to the 
immunization protocol, which favors activation via MHC class II. Similarly, the adoptive transfer 
of pure encephalitogenic CD4+ T cell lines, but not CD8+ T cells, has been successfully used to 
induce passive EAE (Wekerle et al., 1994b). Nevertheless, in MS patients, the ratio of CD4+ to 
CD8+ T cells in CNS lesions is 1:4, and clonal expansion is detected more frequently among 
CD8+ than CD4+ T cells (Friese and Fugger, 2005). In addition, specific depletion of only CD4+ T 
cells in patients did not result in the amelioration of the disease, while treatment with antibodies 
against CD52, depleted multiple lymphocyte populations, including CD4+ and CD8+ T cells 
resulted in reduced number of circulating lymphocytes (Coles et al., 2012).  
Distinct effector T cell subsets have been described to mediate EAE pathogenesis (Friese and 
Fugger, 2005). Naive CD4+ T cells can be differentiated into various subclasses of T helper (Th) 
cells depending on the cytokine milieu. IL-12 and IL-18 induce differentiation into Th1 cells, 
secreting interferon-gamma (IFN-γ). High concentrations of IL-4, however, yield Th2 cells that 
produce IL-4, IL-5, and IL-13. A third subpopulation of effector T cells are Th17 cells, secreting 
IL-17 and IL-22, which can be induced by transforming growth factor beta (TGF-β) and IL-6. In a 
similar cytokine milieu with high concentrations of TGF-β but void of IL-6, naive CD4+ T cells do 
not differentiate into Th17 but rather into Treg cells, that can reduce inflammatory reactions 
(Leung et al., 2010). Those different CD4+ T cell populations get even more complex, since 
certain plasticity between Th cell subpopulations have been observed. In short, mainly Th1 and 
Th17 cells drive inflammation and contribute to pathogenesis, while Treg cells provide a 
controlled immunological environment (El-behi et al., 2010). 
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1.3.3.2  B lymphocytes in MS and EAE 
The superior importance of T cells as initiator and perpetuator of MS became clear from animal 
models of EAE. Yet other lines of evidence suggest B cells have a major role in autoimmune 
diseases either via secreting autoantibodies and cytokines or acting like APCs (Berer et al., 
2011b).  
Brain and CSF of patients with MS contain high concentrations of antibodies (Kabat et al., 
1942). These antibodies forms oligoclonal bands (OCB) of immunoglobulin that mainly involves 
the IgG1 and IgG3 isotypes (Losy et al., 1990). These bands are still an important diagnostic 
marker for chronic CNS inflammation in MS. Interestingly, the antibody response seems to be 
stable over long periods and involve a limited number of clonotypes (Walsh et al., 1986). 
Clonally expanded brain resident B cells are partially accountable for the emergence of these 
oligoclonal bands, stressing the importance of B cells for the development or course of the 
disease (Obermeier et al., 2008). Indeed, ectopic lymphoid follicles were described, enriched 
with B cells and plasma cells in the meninges, potentially providing a suitable microenvironment, 
where B cells can mature, expand, and locally produce autoantibodies (Serafini et al., 2004). 
Autoantibodies also play a major role in EAE, as shown by the transfer of serum from diseased 
animals which induced subclinical demyelination in recipient animals (Lassmann et al., 1981). 
Similarly, active EAE was accelerated and showed exacerbated severity in transgenic IgHMOG 
mice, producing high levels of MOG-specific autoantibodies (Litzenburger et al., 1998). In many 
EAE models, however, the B cell component is missing, since immunization is mostly performed 
with a short encephalitogenic peptide. Thus, immunization with whole myelin proteins offers a 
better understanding of the involvement of B cells in disease development, exacerbation or/and 
protection (Lyons et al., 1999). B cell deficient µMT mice were susceptible to active EAE 
induced by immunization with MOG35-55 peptide, but not by recombinant MOG, suggesting 
differential processing and presentation of the encephalitogenic epitope. On the other hand, 
(Fillatreau et al., 2002) showed that µMT mice failed to recover from active EAE due to lack of B 
cell derived IL-10. 
B cells can also produce cytokines and chemokines (Lund, 2008). Depending on their cytokine 
profile, B cells either promote or suppress immune responses in EAE in animal models. B cells 
produce either Th1 or Th2 associated cytokines when primed with the corresponding Th1 or 
Th2 cells and antigen in vitro (Harris et al., 2000, Harris et al., 2005). However, the existence of 
such cells in vivo remains unclear. The best studied cytokine producing B cells, are murine B10 
or Breg cells which produce IL-10 (Fillatreau et al., 2002), which also have been identified in 
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humans (Duddy et al., 2007). They either inhibit and/or delay the progression of EAE and other 
autoimmune diseases (Fillatreau et al., 2002). 
Antigen presentation by B cells is another important feature that can contribute to the MS 
pathogenesis. It is of particular importance for the T–B cell interactions observed in the 
spontaneous EAE models, as mentioned before. IgHMOG B cells in the OSE mice model present 
MOG proteins to MOG-reactive T cells. This results in mutual activation, proliferation, and 
differentiation and, consequently B cells of those mice produced high titers of MOG-specific 
IgGs (Bettelli et al., 2006, Krishnamoorthy et al., 2006). In the RR mice model, as well as, the 
recruitment of MOG-specific B cells from the endogenous repertoire by MOG-reactive 
transgenic T cells is dependent on the MOG antigen (Pollinger et al., 2009). 
In RR-EAE mice, B cells can contribute to the pathogenesis of EAE in two ways: through the 
production of anti-MOG antibodies seen early in mice lives that contribute to demyelination and 
deposited in CNS (Pollinger et al., 2009). Alternatively, B cells have also been shown to have 
both pathogenic and protective functions depending on the age of the mice (Pollinger et al., 
2009). Therefore, in experiments conducted as part of this thesis, the phenotype and 
characterization of endogenous B cells in RR mice were studied either through MOG-specific B 
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2.  Objectives 
In RR mice model, MOG-specific T cells are known to recruit MOG-specific B cells from their 
natural repertoire. These cells can contribute to the susceptibility or resistance to EAE 
depending on the age of the mice (Pollinger et al., 2009). Therefore, the objectives of the 
present study are: 
 
1. Phenotype and function of MOG-specific B cells.  
2. Clonality of MOG-specific B cells by studying anti-MOG autoantibodies. 
3. Release and/or transportation of neural antigens to peripheral lymphoid organs.  
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3.  Material and Methods 
3.1  Materials 
3.1.1  Cell culture 
EL4: mouse lymphoma cell line induced in a C57BL/6 mouse by 9, 10-dimethyl-1, 2-
benzanthracene treatment (ATCC: TIB-39).  
GPE: the retrovirus packaging Ampli-GPE (clone A57) cells were obtained from NIH3T3 
fibroblasts 
BH-20: the murine monoclonal IgG2a clone against mouse neurofilament light generated from 
SJL/J mouse.   
8.18c5: the murine monoclonal hybridoma against native rat MOG 
 
3.1.2  RPMI 1640 and DMEM (complemented)  
Media Roswell Park Memorial Institute (RPMI) medium 1640 and Dulbecco's Modified Eagle 
Medium (DMEM) (Sigma-Aldrich) were complemented with 100 µM non-essential amino acids, 
1 mM sodium pyruvate, 50,000 units penicillin, 50 mg streptomycin, 2 mM L-glutamine (Gibco), 
and 10% fetal calf serum (FCS) (Biochrome). RPMI 1640 medium was further complemented 
with 200 µM β-Mercaptoethanol. Prior to use FCS was inactivated for 30 minutes at 56°C. 
Media were sterilized by filtration (pore size 0.2 µm). All quantities refer to 500 ml of medium.  
 
3.1.3  Buffers and solutions  
Applied in 
methods 
Buffers and solutions Composition 
3.2  Phosphate buffered saline (PBS) 10 mM Na2HPO4 
1.8 mM KH2PO4 (pH 7.4) 
140 mM NaCl 
2.7 mM KCl 
3.2.3 
3.2.14 
Paraformaldehyde (PFA) solution 4% PFA in PBS 
3.2.5 Heparin solution 5000 units Heparin in PBS 
3.2.5 Lysis buffer 150 mM NaCl 
20 mM Tris-HCl 
1% Triton-X 100 
3.2.6 Erythrocytes lysing buffer 0.83% Ammonium chloride in PBS 
3.2.9 Isotonic percoll solution 9 parts (v/v) of Percoll  
1 part (v/v) of 1.5 M Sodium chloride 
3.2.10 Fluorescence-activated cell sorting 
(FACS) staining buffer 
1% BSA 
0.1% Sodium azide in PBS 
3.2.10 Saponin staining buffer 0.1% (w/v) Saponin in PBS  
3.2.12 
3.2.13 
Blocking buffer  10% FCS in PBS 
3.2.12 H2O2 solution 1% H2O2 
3.2.12 
3.2.13 
Washing buffer  0.05% Tween 20 in PBS 
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3.2.13 Assay Diluent 0.05% Tween 20 in PBS 
3.2.14 Blocking buffer 4% BSA in PBS 
3.2.16 Binding buffer 20 mM Sodium phosphate (pH 7.0) 
3.2.16 Elution buffer 0.1 M Glycine (pH 2.7) 
3.2.16 Neutralization buffer 1 M Tris-HCl (pH 9.0) 
3.2.17 Elution buffer 4 M MgCl2 (pH 6.6-7.2) 
3.2.17 Low salt binding buffer 20 mM Sodium phosphate 
20 mM NaCl 
3.2.17 Ni-NTA column regeneration buffer 1% EDTA  
0.05% Tween-20 
3.2.18 Binding buffer 1.0% Nonidet P-40 in PBS 
3.2.18 Homogenizing buffer 1.0% Nonidet P-40 
Mixture of protease inhibitors in PBS 
3.2.18 Wash buffer  0.1 M Sodium acetate 
0.15 M NaCl  
3.2.19 Deglycosylation reaction buffer 1% MEGA-10 in PBS (pH 7.0-7.2) 
3.2.19 Dialysis buffer 6 M Urea  
20 mM Tris  
3.2.20 Agarose solution 0.5 g Agarose  





0.1 g APS in 1 ml H2O 
3.2.20 
3.2.21 
Coomassie staining solution 0.1 g Coomassie R-250 
50% Methanol 
7% Acetic acid 
3.2.20 
3.2.21 
Destaining solution 50% Methanol 
7% Acetic acid 
3.2.20 ELPHO buffer 10x  1% SDS  
0.24 M Tris  
1.92 M Glycine  
3.2.20 Equilibration buffer 6 M Urea  
4% SDS  
30% Glycerol 
50 mM Resolving gel buffer 1.5 M 
0.5% Bromophenol 
3.2.20 Immobilized pH gradient (IPG) gel 
rehydration buffer 
8 M Urea  
2 M Thiourea  
2% (v / v) Resolyte 3-10 
0.5% Bromophenol 
3.2.20 Isoelectric focusing (IEF) loading 
buffer 
6 M Urea 
2 M Thiourea 
0.5% bromophenol 
3.2.20 Non-reducing denaturing sodium 
dodecyl sulfate (SDS)-loading 
buffer 5x 
0.2 M Tris-HCl (pH 8.0) 
1.5% SDS  
4.5 ml Glycerol 
0.02% Bromophenol  
3.2.20 
 
Reducing SDS-loading buffer 3x 0.15 M Tris-HCl (pH 6.8) 
15% SDS  
45 g Glycerol 
6% ß-Mercaptoethanol 
0.01% Bromophenol  
3.2.20 Resolving gel buffer 1.5 M Tris-HCL (pH 8.8) 
0.4% SDS  
3.2.20 SDS solution 1% SDS 
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3.1.4  Antibodies and staining reagents 
FACS markers specificity  Clone  Antibody class  Company  
Bcl-6 GI191E Mouse IgG1 eBioscience 
CD3ε  145-2C11  Ar Ham IgG1, κ  BD Biosciences 
CD4  RM4-5  Rat IgG2a, κ  eBioscience  
CD5  53-7.3  Rat IgG2a, κ  BD Biosciences 
CD11b  M1/70  Rat IgG2b, κ  BD Biosciences 
CD11c N418 Ar Ham IgG eBioscience 
CD19  1D3  Rat IgG2a, κ  BD Biosciences 
CD21  7G6  Rat IgG2b, κ  BD Biosciences 
CD23  B3B4  Rat IgG2a, κ  BD Biosciences 
CD24  M1/69  Rat IgG2b, κ  BD Biosciences 
CD25  PC61 Rat IgG2b κ  eBioscience  
CD27 LG.7F9 Ar Ham IgG eBioscience 
CD38 90 Rat IgG2a κ eBioscience 
CD45 30-F11 Rat IgG2b, κ eBioscience 
CD45.1 A20 Ms IgG2a k eBioscience 
CD45.2 104 Ms IgG2a κ BD Biosciences 
CD45R/B220  RA3-6B2  Rat IgG2a κ  eBioscience  
CD95 Jo2 Ar Ham IgG2 λ2 BD Biosciences 
CD138 281-2  Rat IgG2a κ BD Biosciences 
CD154 MR1  Ar Ham IgG3 κ BD Biosciences 
F4/80  Cl:A3-1  Rat IgG2b κ  AbD Serotec  
Gl7 Gl7 Rat IgM κ BD Biosciences 
Igλ1,2,3 light chain R26-46 Rat IgG2a κ BD Biosciences 
Igκ light chain 187.1 Rat IgG1 κ BD Biosciences 
IgD 11-26c.2a  Rat IgG2a κ BD Biosciences 
IgE 23G3 Rat IgG1 κ eBioscience 
IgG1 A85-1 Rat IgG1 κ BD Biosciences 
IgG2a/b R2-40 Rat IgG1 κ BD Biosciences 
IgM  R6-60.2  Rat IgG2a κ  BD Biosciences 
IgM II/41  Rat IgG2a, κ BD Biosciences 
IgMa DS-1 Ms IgG1 κ  BD Biosciences 
MOG (8.18c5) 8.18-C5 Mouse IgG1 Max Planck Institute of 
Neurobiology 
MOG (Z2) Z2 Mouse IgG2a - 
mMOG-biotin-tetramer - - Max Planck Institute of 
Neurobiology 
mOVA-biotin-tetramer - - Max Planck Institute of 
Neurobiology 
Peanut agglutinin - - Sigma 
Streptavidin  -  -  eBioscience  
Streptavidin-HRP   eBioscience 
TO-PRO-3  -  -  Invitrogen  
Vα8.3 TCR KT50  Rat IgG2a κ  BD Biosciences 
Vβ4 TCR KT4 Rat IgG2b κ BD Biosciences 
Viability dye - - eBioscience 





Clone  Antibody class  Company  
IgG1a 10.9 Ms IgG2a, κ BD Biosciences 
IgG1b B68-2 Ms IgM, k  BD Biosciences 
IgG2aa 8.3 Ms IgG2a, κ  BD Biosciences 
IgG2ab 5.7 Ms IgG3, k BD Biosciences 
IgMa DS-1  Ms IgG1, κ  BD Biosciences 
IgMb AF6-78 Ms IgG1, κ  BD Biosciences 
Immunohistochemistry 
(IHC) 
Clone  Antibody class  Company  
CD4 RM4-5  Rat IgG2a, κ BD Biosciences 
CD45R/B220 RA3-6B2 Rat IgG2a, κ BD Biosciences 
DAPI - - Invitrogen 
MBP - Rat IgG2a, κ Milipore 
MOG (Z2) - Mouse IgG2a Max Planck Institute of 
Neurobiology 




Clone  Antibody class  Company  
IgG -  Goat IgGγ Southern Biotech 
 
3.1.5  Primers 
Primer name Gene Oligo sequence (5' -> 3') 
mGAPDH sense #1 GAPDH TCA CCA CCA TGG AGA AGG C 
mGAPDH anti-sense #2 GAPDH GCT AAG CAG TTG GTG GTG CA 
mGAPDH probe #3 GAPDH ATG CCC CCA TGT TTG TGA TGG GTG 
T 
mCD19 sense #1 CD19 GGA AAA GGA AGC GAA TGA CTG A 
mCD19 anti-sense #2 CD19 AGA GCA CAT TCC CGT ACT GGT T 
mCD19 probe #3 CD19 CGC CAG GAG ATT CTT CAA AGT GAC 
GC 
C3-Vβ4 sense #1 C3 Vβ4 TCR TGA TGA CTC GGC CAC ATA CTT C 
C3-Vβ4 anti-sense #2 C3 Vβ4 TCR CCT GAG CCA AAA TAC AGC GTT T 
C3-Vβ4 probe #3 C3 Vβ4 TCR TGC CAG CAG CCA AGA ACG GAC 
AGA T 
C3-Vα 8.3 sense #1 C3 Vα8.3 TCR CCA CGC CAC TCT CCA TAA GAG 
C3-Vα8.3 anti-sense #2 C3 Vα8.3 TCR CAG TAG TAC AGG CCA GAG TCT 
GAC A 
C3-Vα8.3 probe #3 C3 Vα8.3 TCR AGC AGC TCC TTC CAT CTG CAG AAG 
TCC 
 
3.1.6  Mouse license  
Animals used during the studies of this dissertation were bred at the Max Planck Institutes of 
Biochemistry and Neurobiology animal facilities under specific pathogen free (SPF) conditions. 
The experimental procedures were approved by the local authorities. 
Material and Methods  
21 
3.2  Methods  
3.2.1  EAE induction: 
Mice were injected subcutaneously (s.c) at the back with 200 µl of recombinant MOG (200 µg), 
which was emulsified in Freund's adjuvant supplemented with 3 mg/ml Mycobacterium 
tuberculosis (strain H37Ra). 200 ng of pertussis toxin was injected intraperitoneal (i.p) on days 0 
and 2 after immunization. Clinical scoring of classical paralytic EAE was performed as follows: 
score 0, healthy; 1, flaccid tail; 1.5, flaccid tail and impaired righting reflex; 2, impaired righting 
reflex and hind limb weakness; 2.5, one hind leg paralyzed; 3, both hind legs paralyzed with 
residual mobility in both legs; 3.5, both hind legs completely paralyzed; 4, both hind legs 
completely paralyzed and beginning front limb paralysis; and 5, moribund or death of the animal 
after preceding clinical disease.  
 
3.2.2  Alum immunization:  
Mice were injected with 100 µg of rMOG/OVA i.p 200 µl per mouse. Protein is precipitated 
(rOVA and rMOG) in 10% alum KAl(SO4)2 (Sigma) with 5 N NaOH (Merck). The precipitated 
protein solution and the alum 1:1 were calibrated to a pH of 6.5-7.5 with NaOH (Merck). Then, 
the precipitated protein was incubated on ice for 30 minutes, washed 2 times with PBS and 
resuspended in PBS for i.p injection. 
 
3.2.3  Intracardiac perfusion:  
In anesthetized mice, the thoracic cavity was opened and a butterfly needle was inserted into 
the left ventricle of the heart. After incising the right atrium, mice were slowly perfused with 20 
ml of PBS then another 20 ml of 4% PFA in PBS for later dissection and histological analysis. 
 
3.2.4  Intrathecal injection: 
Mice were anesthetized by intraperitoneal injection of ketamine (10  mg/kg of body weight; 
Imalgene 500; Rhône-Merieux, Lyon, France) and xylazine (1  mg/kg of body weight; Rompun; 
Bayer). Mouse was fitted into a stereotaxic apparatus, between 10-40 µl of 20 µg of mMOG or 
mMOG-FITC were slowly injected into the CSF through a 30-gauge needle and a Hamilton 
syringe inserted in the bregma point of the mouse skull. Full recovery of treated mice and FACS 
analysis of presence or absence of lymphocytes infiltration to the CNS confirmed appropriate 
access to the intrathecal space and the success of the procedure.  
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3.2.5  Leukocyte isolation from peripheral blood: 
Two to five droplets of blood were collected from anesthetized mice by retro-orbital bleeding into 
100 µl of 200 U/ml heparin (Sigma-Aldrich) in PBS. Erythrocytes were lysed by incubation in 1 
ml erythrocytes lysing buffer; leukocytes were then centrifuged at 500 relative centrifugal force 
(rcf) for 5 minutes, washed with 1 ml erythrocytes lysing buffer, and finally resuspended in 200 
µl in FACS buffer. 
 
3.2.6  Lymphocyte preparation from isolated organs: 
Mice were sacrificed and lymphoid organs were collected. Single cell suspensions were 
obtained by dissociating tissues through 40 µm cell strainers (BD Biosciences). Cells were 
centrifuged at 500 rcf for 10 minutes at 4°C and resuspended in complemented RPMI for 
culturing or further downstream analyses. For spleen or bone marrow preparations, an 
additional erythrocyte lysing step was performed by incubating the cell suspension in 0.83% 
NH4Cl for 3 minutes at room temperature (RT) and washed with RPMI medium. 
 
3.2.7  Cultivation of cell lines:  
Cell lines or primary cells were cultivated in fully complemented RPMI or DMEM medium in 
standard cell culture-treated plastic dishes (BD; Nunc, Denmark; Corning) in a humidified 
incubator (Heraeus) at 37°C and, 5% or 10% CO2, respectively. Cells growing in suspension 
were harvested by resuspending the culture; semi-adherent cells were flushed off the culture 
dish surface; and adherent cells were first briefly rinsed with PBS and then trypsinized with 
Trypsin-EDTA (PAA Laboratories) for 3 to 5 minutes at 37°C. Cell densities were regularly 
determined using a Neubauer hemocytometer (Neubauer). Cultures were kept subconfluent by 
regular dilution with fresh medium at ratios from 1:2 to 1:10. Cells were pelleted by 
centrifugation at 250 rcf for 10 minutes at 4°C and resuspended in complemented RPMI for 
culturing or further downstream analyses.  
 
3.2.8  Whole organ culture: 
Splenocytes and lymph nodes from mice were dissected and cultivated in fully complemented 
DMEM medium in standard cell culture-treated plastic dishes (BD; Nunc, Denmark; Corning). 
These were manually fitted with filters at the bottom of each well (Millipore) in a humidified 
incubator (Heraeus) at 37°C and 10% CO2. 
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3.2.9  Isolation of CNS mononuclear cells: 
Mouse brain was dissected out and the entire spinal cord was flushed out with a syringe from 
the animal and pressed through nylon mesh into RPMI medium (without serum). After 
centrifugation for 10 minutes at 500 rcf, it was suspended in 5 ml of RPMI and mixed with 2.16 
ml of isotonic percoll solution (Amersham Biosciences). The cell suspension was overlaid on 5 
ml percoll and centrifuged 1200 rcf for 20 minutes at 20°C. The interface containing the 
mononuclear cells were collected and washed once with RPMI. 
 
3.2.10  Fluorescence-activated cell sorting (FACS): 
Cells to be analyzed were transferred into 96-well V-bottom plates and centrifuged at 500 rcf for 
10 minutes at 4°C. Cells were washed in 200 µl FACS buffer twice, resuspended in 50 µl FACS 
buffer containing FC blocker (eBioscience) incubated for 10 minutes and washed with FACS 
buffer. For surface staining, cells were incubated with directly labeled surface marker-binding 
antibodies at appropriate dilutions, for 20 minutes at 4°C. After surface staining, cells were 
suspended in PFA/saponin buffer for 10 minutes in the dark, washed twice with saponin buffer 
after which flurochorome-labeled antibodies were added and incubated for another 30 minutes. 
In some samples, viability dyes or TO-PRO-3 were included (eGFP-PLP samples). Biotinylated 
antibodies were visualized by streptavidin-APC (BD Pharmingen). After washing and 
resuspension in 100 µl FACS buffer, samples were acquired on a FACS Calibur or FACS Canto 
or Aria (all FACS machines from BD), and analyzed using FlowJo 7.6 software (TreeStar).  
 
3.2.11  Serum collection:  
Mice were bled by retro-orbital puncture, and the samples were allowed to clot overnight at 4°C. 
Serum was collected after centrifugation at 400 rcf for 10 minutes at 4°C and stored at -20°C 
until further analyses. 
 
3.2.12  Enzyme linked immunosorbent (ELISA) assay:  
ELISA plates (Nunc) were coated with rMOG (10 µg/ml in PBS), overnight at 4°C. Plates were 
washed with washing buffer and blocked with assay diluent for 1 hour. They were then washed 
and incubated with 100 µl of sample at RT for 2 hours. Plates were then washed, and 100 µl of 
the respective biotinylated secondary antibodies diluted in assay diluent was added and 
incubated for another 1 hour. After extensive washing, streptavidin-HRP (1:2000) was added 
and incubated at RT for 30 minutes. After washing, 100 µl of ABTS (2, 2’-Azino-bis-3-ethyl-
benzthiazoline-6-sulphonic acid; Sigma) activated with H2O2 was added and absorbance was 
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measured at 405 nm in an ELISA reader (Victor2™ 1420 Mutilabel counter; Perkin Elmer life 
sciences). 
 
3.2.13  Enzyme linked immunospot (ELISPOT) assay:  
Multiscreen HTS filter plates (Millipore) pre-wetted with 15 µl EtOH (35% in PBS) for 1 minute 
were coated with 50 µl of 20 µg of rMOG in PBS and incubated overnight at 4°C. The next day 
the plates were blocked with 200 µl of 10% FCS in complete RPMI for 2 hours at 37°C. Total 
splenocytes or lymph nodes cells were resuspended (106/ml) in complete 10% FCS RPMI 
medium, seeded in the plates and incubated for 2 hours at 37°C in cell culture incubator (5% 
CO2 and 95% H2O). After washing the plates, 100 µl of biotinylated antibody diluted in 1% 
Tween 20 in PBS were added and plates were incubated for 2 hours at 37°C. After which plates 
were decanted and washed carefully with running water. Plates were treated with 50 µl 
streptavidin (eBioscience), incubated for 20 minutes and were developed with 25 µl BCIP/NBT 
(BIOZOL). The reaction was then stopped by running water and spots were counted by an 
ELISPOT reader (Carl Zeiss). 
 
3.2.14  Fluorescence microscopy:  
Tissue sections: Organs from PFA perfused mice were fixed in 4% PFA in PBS for 1 hour, and 
then immersed in 30% sucrose, overnight. Tissues were embedded in tissue-tek O.C.T. 
compound (Sakura), and 10 µm sections were cut on a CM3050 S Cryocutter (Leica).  
Fluorescence immunohistochemistry: Tissue sections were fixed in cold acetone for 5 
minutes, and blocked with 4% BSA in PBS for 2 hours at RT. Incubation with primary antibody 
(rat monoclonal, 1:200-400) was done in 4% BSA in PBS for 2 hours or overnight at 4°C. 
Incubation with fluorescently-labeled secondary antibody (anti-rat IgG goat polyclonal, 1:2000, 
Invitrogen) was done in 4% BSA in PBS for 2 hours at RT. Cell nuclei were stained with DAPI 
(Invitrogen) in PBS for 5 minutes at RT, before sections were eventually rinsed with PBS and 
embedded in anti-fading mounting medium (Sigma-Aldrich). Images were acquired on an 
inverted SP2 confocal microscope (Leica) or an inverted AxioVert 200 M microscope (Carl 
Zeiss). 
Image analysis: Time-lapse images were acquired using Leica LCS software (Leica, Wetzlar), 
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3.2.15  Hybridoma generation:  
Splenocytes from the RR mice were cultured in unstimulated condition and stimulated condition 
with 20 µg/ml LPS (E. coli serotype O111:B4) in vitro. After 3 days, cells were washed 
extensively to remove the serum. The hybridoma fusion partner cell line, Sp2/0 growing in 
exponential phase, was also harvested and washed. Splenocytes were mixed with Sp2/0 cells 
(5:1), and 0.5 ml of 50% polyethylene glycol was added slowly while mixing gently. Cells were 
kept at 37°C for 1 minutes, diluted with serum-free media, centrifuged and plated in 96-well 
plates at 1-2×106 cells/ml in Hybrimax® HAT (Sigma) containing DMEM/20% FCS. Seven days 
later medium was replaced with Hybrimax® HT (Sigma) containing DMEM/20% FCS and 
growing clones were expanded in DMEM/10% FCS. Sub-cloning was done manually by serial 
dilution. 
 
3.2.16  Antibodies purification from blood serum:  
Diluted serum from mice were filtered and applied to the Hitrap ® protein G column (Amersham 
Biosciences). These were washed extensively with binding buffer to remove non-binding 
proteins. Antibodies were eluted from the column with the elution buffer and immediately 
neutralized with the neutralization buffer. The antibodies-containing fractions (measured by OD 
280) were pooled and dialyzed against PBS, overnight. 
 
3.2.17  Purification of anti-MOG antibodies:  
HiTrap chelating HP column was prepared by loading it with 1% NiCl2 from which excess nickel 
was removed by washing with H2O. Histidine-tagged rOVA protein in low salt binding buffer was 
loaded to the column and washed extensively. Then, protein G purified antibody from mice 
serum was passed through the column. The flow-through was collected and passed through 
another nickel-loaded HiTrap chelating HP column conjugated to mMOG or rMOG. MOG-
specific antibodies were eluted with 4 M MgCl2. The antibodies-containing fractions (measured 
by OD 280) were pooled and dialyzed against PBS, overnight.  
  
3.2.18  Antibodies purification from CNS:  
Frozen brain and spinal cord were thawed and extensively washed with PBS. It was then 
mashed by pressing it into 100 µm nylon strainers (BD). CNS was homogenized in ice-cold 
homogenizing buffer using a glass Dounce apparatus (0.1 g of tissue per milliliter of buffer). 
Insoluble material was removed by centrifugation at 20,000 rcf for 20 minutes (SS-34 rotor: 
129,000 rpm at 4°C). The pellet was re-homogenized and centrifuged two additional times. The 
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supernatants were pooled and clarified by centrifugation at 60,000 rcf (SW-28 rotor: 18257.52 
rpm) for 60 minutes (O’Connor et al., 2005). The clarified supernatant was loaded onto a 
column containing 5 ml of streptavidin agarose conjugated beads (Milipore, Cat 16-126) to 
remove impurities. The collected flow through, was passed through Protein G (protein G 
sepharose, CAT 17-0618-01) and the purity of the isolated IgG was assessed by running a 
SDS-PAGE gel under reducing conditions. 
 
3.2.19  Deglycosylation of purified anti-MOG antibody:  
Homogeneity of purified anti-MOG antibodies on IEF gels was increased by heating samples to 
95°C for 1 minutes, and incubated for 3 hours at 37°C in the presence of 1 % MEGA-10 (w/v) at 
pH 7.2 with 100 U/ml N-Glycosidase F recombinant (Roche). The samples were then dialyzed in 
a D-tube Dialyzer Mini MWCO 12-14 kDa (Novagen) against 6 M urea, for 2 hours using a 
magnetic stirrer at RT, and then for 15 minutes at 50 V in a flatbed gel electrophoresis chamber 
to remove residual SDS. 
 
3.2.20  Two dimensional (2D) gels: 
Isoelectric focusing (IEF) first dimension (separation according to charge): IPG 
rehydration buffer was added to the eluted samples and loaded onto rehydrated 24 cm 
Immobiline DryStrip pH 3-10 gel (GE Healthcare). 3100 OFFGEL Fractionator (Agilent) in the in-
gel mode was used according to the manufacturer’s recommendations, but with two essential 
exceptions. First, instead of rehydrating the IEF strips together with the eluted samples, the 
loading cup (8 x 2 mm, conical) was placed onto the rehydrated strip at pH 4.5. Second, the 
default focusing method was set to a slower voltage-increase and extended duration as follows: 
for the first 30 minutes the voltage was limited to 500 V and then for 30 minutes to 1000 V. 
During electrophoresis the maximum values were 8000 V, 50 µA and 200 mW until 120 kVh 
were reached. The IEF strips were then equilibrated for 20 minutes on a slow shaker in 
equilibration buffer.  
SDS-polyacrylamide gel second dimension (separation by size): IPG strips, after 
completion of IEF, were left at RT in equilibration buffer. To fit into the 2D Noves pre-casted gel 
(Invitrogen), the IPG strips were cut 2 cm shorter from the anode and 1 cm from the cathode 
and, briefly immersed in 1x ELPHO buffer. An agarose solution was poured and left to be 
polymerized for 15 minutes. Electrophoresis was then performed in ELPHO running buffer in a 
mighty small gel chamber (Hoefer) for 4 hours at 10 mA. 
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SDS-PAGE: Separation of proteins was achieved by denaturing, discontinuous, SDS 
polyacrylamide gel electrophoresis, using precast Novex 4-12% tris-glycine gels (Invitrogen). 
Protein samples were boiled for 5 minutes at 100°C, before being loaded to each lane. 
Electrophoresis was performed in running buffer at 100 V for stacking, and at 130 V for 
resolving of proteins in a mighty small gel chamber (Hoefer). Gels were stained with Coomassie 
brilliant blue G-250 (Bio-Rad) in order to verify appropriate sample loading. 
 
3.2.21  Native gel:  
Protein was separated on a 10% polyacrylamide (19 acrylamide: 1 bis-acrylamide) gel in non-
denaturing conditions. Buffers used are similar to those describe for SDS-PAGE except for the 
removal of SDS and ß-mercaptoethanol. 
 
3.2.22  F(ab)’2 fragmentation:  
F(ab)’2 fragmentation of Z2 antibody was performed according to manufacturer’s protocol 
(Pierce protein biology products, Thermo scientific) and the products were electrophoresed 
under non-reducing conditions. 
 
3.2.23  RNA techniques  
RNA extraction: Total RNA was isolated from purified cells or whole tissue by TRI Reagent 
(Sigma-Aldrich) following the instructions provided by the manufacturer. 
Reverse transcription: cDNA was generated from RNA using SuperScript II Reverse 
Transcriptase (Invitrogen) or the Verso cDNA Kit (Thermo Fisher Scientific), according to the 
manufacturer´s instructions.  
Quantitative PCR: Real-time qPCR was performed using the Absolute qPCR Mixes (Thermo 
Fisher Scientific) according to the instructions of the manufacturer. Samples were then amplified 
using a 7900HT Fast Real-Time PCR System (Applied Biosystems) and analyzed by SDS 2.3 
software (Applied Biosystems). 
 
3.2.24  Statistical analysis 
Linear regression and unpaired t tests analysis were performed using Graphpad software 
(Graphpad, La Jolla, CA). 
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4.  Results 
4.1  MOG-binding B cells in RR mice 
4.1.1  mMOGtet: A tool to detect MOG-binding B cells 
Each B cell expresses one B cell receptor (BCR) with a single antigen binding specificity. While, 
the immune system can react to a vast number of antigens, only few thousands of B cells 
express receptors that are specific for any given antigen. Therefore, the experimental 
identification of antigen-specific B cells was a challenging task, due to the low frequency of cells 
with specific receptors for any particular antigen, which is usually less than 1% (Scheid et al., 
2009). Antigen-specific B cells can be detected using fluorescently labeled antigen(s), and to 
boost the avidity of antigen of interest, antigens tetramerization was routinely used. 
To detect MOG-binding B cells in RR mice, the extracellular portion of mouse MOG peptide 
(MOG1-125) was expressed and multimerized (Figure 4.1A). Mouse MOG1-125 was expressed in 
human embryonic kidney cells (HEK) transformed with EBNA-1 gene cell line. HEK-EBNA-1 is a 
mammalian eukaryotic protein expression system that has multiple advantages over prokaryotic 
systems. The most relevant advantage is those only correctly folded proteins are secreted, 
namely proteins, which retain their sulfide-sulfide bonds and their correct glycosylation pattern 
(Figure 4.1C). Purified MOG1-125 peptides from HEK cells were biotinylated with BirA ligase in 
order to multimerize them to form tetramers. Tetramerization was achieved based on the ability 
of streptavidin (SA) to spontaneously assemble stable tetramer-structures composed of four 
MOG1-125 peptide monomers (mMOGtet) (Figure 4.1D). Additionally, mammalian chicken 
ovalbumin protein (mOVA) was also prepared in a similar fashion as a control. The construct of 
both mMOGtet and mOVAtet contain Igκ signal peptides to guide the proteins to the secretory 
pathway outside of the cell. The synthetic proteins were also biotin tagged for tetramerization 
purposes and histidine tagged to separate them from other cellular proteins (Figure 4.1A).  
Mammalian cell produced mouse MOG tetramers (mMOGtet) differ from rat recombinant MOG 
(rMOG) in many aspects as listed in the table in Figure 4.1C. For example, despite the high 
homology between rat and mouse, a peptide of mouse- rather than rat- origin such as mMOG 
might increase binding affinity to MOG-binding B cells in mice. Secondly, and most important, is 
the preservation of the conformational structure that is only guaranteed by mMOG expressed in 
a eukaryotic system. Thirdly, the glycosylation pattern of secreted mMOG is preserved as seen 
by the slightly heavier molecular weight of mMOG monomers in the SDS-PAGE gel (Figure 
4.1B). All this might increase the chance of detecting B cells in mice.  
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In order to validate the efficiency of mMOGtet compared to rMOG in binding to MOG-specific B 
cells, mMOGtet specificity and sensitivity to MOG-binding B cells were evaluated in several 
experiments. First, the MOG-specific hybridoma cell line 8.18c5 that produces and secretes 
conformation-dependent anti-MOG monoclonal antibodies (mAb) was used to test the specificity 
of mMOGtet compared to monomeric rMOG. mMOGtet had a higher affinity to 8.18c5 hybridoma 
cell line than rMOG as seen by the shift of signals in the histogram of the mMOGtet stained 
8.18c5 hybridoma cell line compared to rMOG stained 8.18c5 hybridoma cell line (Figure 4.2A). 
The staining of irrelevant hybridoma cell line such as the neurofilament light-specific BH-20 
hybridoma cell line with either mMOGtet or rMOG remained at the background level (Figure 
4.2A). Second, B cells in IgHMOG transgenic mice, which were engineered to express on its BCR 
the MOG-specific 8.18c5 immunoglobulin H chain, were used in sensitivity and specificity tests. 
rMOG bound to about half of MOG-binding B cells in IgHMOG mice while mMOGtet detected up to 
80% of total B cells population in IgHMOG mice, presumably labeling even low affinity B cells 
(Figure 4.2C). A control staining with streptavidin-conjugated fluorochrome (Figure 4.2C) did not 
produce any staining in IgHMOG mice. Also, mMOG monomers captured more serum anti-MOG 
antibodies from IgHMOG compared to rMOG monomers in ELISA assay (Figure 4.2B).  
Figure 4.1. Construction of mMOG tetramer (mMOGtet). A) A schematic diagram of mMOG1-125 peptide 
and mOVA protein constructs which consists of Igκ signal peptide, biotin tag and histidine-tag. B) SDS-PAGE 
gel shows molecular weight of rMOG compared to mMOG monomer. C) A table shows major differences 










Ig signal peptide 














eukaryotic cell line 
Mouse MOG Glycosylated Natively preserved 
rMOG Bacterial prokaryotic 
cell line 








The specificity of mMOGtet was further tested in different experimental settings compared to its 
staining control tetramer mOVAtet. Aluminum hydroxide (alum) was used to precipitate protein of 
interest (MOG and OVA) and immunize mice to enhance the percentage of antigen-specific B 
cells. Upon rMOG-alum immunized SJL/J WT mice developed almost 1% of MOG-binding B 
cells which were detected by mMOGtet staining while, rOVA-alum immunized mice showed up to 
3% OVA-binding B cells when stained with mOVAtet (Figure 4.3A). In addition, there were 
negligible amount of OVA-binding B cells detected in rMOG-alum immunized mice and vice 
versa (Figure 4.3A). These results confirmed that mMOGtet is a specific reagent that can detect 
low affinity MOG-binding B cells more efficiently than rMOG. Therefore, mMOGtet along with its 
control reagent mOVAtet were used in a sensitivity test. IgHMOG C57BL/6 splenocytes were 
mixed into SJL/J WT splenocytes at different ratios. Serially diluted IgHMOG B cells were 
detected via allotype specific antibody (IgMa for C57BL/6 cells) and mMOGtet. MOG-binding B 
cells were found in all dilutions with expected proportions (Figure 4.3B). Percentages of MOG-
binding B cells were halved in each diluted sample compared to the previous sample, and it was 
able to detect MOG-binding B cell of frequency less than 0.2% (Figure 4.3B). These results 
confirmed that mMOGtet is a sensitive reagent that can detect even low affinity MOG-binding B 
cells compared to rMOG.  
 
Figure 4.2. mMOGtet: a tool to stain MOG-binding B cells. A) Histogram shows mMOGtet staining 
compared to rMOG on anti-MOG 8.18c5 hybridoma cell line and a control neurofilament light BH-20 
hybridoma cell line. B) ELISA assay shows that IgHMOG mice serum antibodies bound better to mMOG 
compared to rMOG monomers. C) Representative flow cytometric plots of B cells from IgHMOG mice stained 
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Therefore, mMOGtet along with its control reagent mOVAtet were used in subsequent 
experiments.  
 
4.1.2  MOG-binding B cells in lymphoid organs 
mMOGtet was used to identify naturally recruited MOG-specific B cells in RR mice. MOG-binding 
B cells were detected within B cell population via mMOGtet in RR mice and they are distributed 
in all lymphoid compartments with different frequencies (Figure 4.4A). Healthy and sick RR mice 
have significantly more MOG-binding B cells compared to SJL/J WT mice. As anticipated, 
healthy RR mice have MOG-binding B cells that tend to accumulate in the CNS-draining 
cervical and lumbar lymph nodes compared to other lymphoid compartments such as axillary 
and inguinal lymph nodes (Figure 4.4A). Surprisingly, in severely sick RR-EAE mice MOG-
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Figure 4.3. Tetrameric antigens (MOG/OVA) staining were sensitive and specific. A) Flow cytometric 
analysis shows MOG- and OVA-binding B cells in splenocytes from rMOG and rOVA alum immunized mice 
and SJL/J WT mice using mMOGtet and mOVAtet reagents. B) Flow cytometric analysis of mMOGtet binding to 
IgHMOG splenocytes mixed with C57BL6 WT splenocytes at various ratios. Data are representative of at least 
two independent experiments (n=2/group).  
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binding B cells are seen in comparable percentages in the CNS draining lymph nodes and the 
rest of lymphoid compartments, as well as, bone marrow (Figure 4.4A). ELIspot has also 
revealed that there are antibody-producing cells in RR mice, starting at age of 6 weeks (Figure 
4.4B). Splenocytes and bone marrow cells from RR mice and their wild type counterparts at 3 
and 6 weeks were cultured overnight without any stimulation, which resulted in the formation of 
IgG spot forming cells only in RR mice at age of 6 weeks (Figure 4.4B). Collectively, MOG-
binding B cells tend to accumulate in CNS draining lymph nodes before the onset of disease 
and antibody-producing cells are found as early as 6 weeks of age in RR mice.  
Mature B cells when stimulated with their specific antigen; find their way to enter germinal 
center (GC) reaction. Germinal centers grant somatic hyper-mutation and isotype switching of B 
cells to increase their BCR specificity and production. In RR mice, the percentage of MOG-
binding B cells in blood lymphocytes increased with disease severity, reaching a maximum of 
0.8% of total B cell population (Figure 4.5A). At the same time, during the peak of the disease, 
the germinal center reaction of the cervical lymph was the highest compared to other lymphoid 
Figure 4.4. MOG-binding B cells were found in all immune cell compartments in RR mice. A) Percentage 
of MOG-binding B cells detected by mMOGtet reagent in the indicated immune cell compartments gated on 
B220+ B cells (SPL: spleen, mLNs: mesenteric lymph nodes, BM: bone marrow, cLNs: cervical lymph nodes, 
LLNs: lumbar lymph nodes, aLNs: axillary lymph nodes, iLNs: inguinal lymph nodes). B) ELIspot shows IgG 
spot-forming cells in 3, 6 weeks old RR and SJL/J WT mice. Graphs are representative of at least two 





organs (Figure 4.5B). Therefore, it was feasible to detect MOG-binding B cells in germinal 
center reactions of severely diseased RR mice in the CNS draining lymph nodes, that is cervical 
nodes that contain ∼1% to 1.6% of MOG-binding B cells (Figure 4.5C). The specificity and 
functionality of this population were verified by 10 days ex vivo organ cultures assay. Cervical 
lymph nodes’ supernatant contained the highest amount of anti-MOG antibodies compared to 
other lymphoid organs (Figure 4.5D) in RR mice.  
 
Usually, germinal center B cells evolve to either plasma blasts or plasma cells. The plasma cell 
CD138 marker was increased in RR mice lymph nodes compared to SJL/J WT mice (Figure 
4.6A). However, unexpectedly, plasma cells did not bind to MOG when stained with mMOGtet 
intracellularly (data not shown). Nevertheless, RR mice contained high percentages of IgG1 
positive cells in immune cell compartments -but not IgG2a/2b-compared to SJL/J WT mice (Figure 
4.6B), and anti-MOG antibody-producing cells as defined by low expression of B220, and high 
Figure 4.5. MOG-binding B cells were detected in GC. A) Frequency of MOG-binding B cells in the blood 
increased with disease severity. B) GC reaction in different lymphoid compartments of RR mice compared to 
SJL/J WT mice. C) Flow cytometric plots of cervical lymph nodes from sick RR mice with a score of 3 shows 
MOG-binding B cells detected in GC reactions seen by GL7, Bcl6 and Fas expression. D) IgG1 MOG ELISA 
from supernatant of ex vivo organs’ culture -at day 4 and day 10-shows MOG-specific GC reaction in spleen 
and lymph nodes (cLNs: cervical lymph nodes, aLNs: axillary lymph nodes, iLNs: inguinal lymph nodes, LLNs: 
lumbar lymph nodes, mLNs: mesenteric lymph nodes, SPL: spleen). Data are representative at least of two 
independent experiments (n=2-4/group). 




























expression of isotyped switched Ig (IgG1). Thus, MOG-binding B220low IgG1high cell population 
tends to accumulate in CNS draining lymph nodes in RR mice (Figure 4.6C).  
 
4.1.3  MOG-binding B cells in the CNS 
RR-EAE mice have higher numbers of CNS infiltrating lymphocytes than healthy or WT SJL/J 
mice (Figure 4.7A and section 4.3.2). The cell infiltrates contained T cells, B cells and CD11b+ 
cells (Figure 4.16); with T cells being more numerous than B cells (Figure 4.7B, 4.17. 4.19). 
Some reports have documented B cell follicles within the CNS, displayed germinal center-like 





Figure 4.6. MOG-binding IgG1 cells. A) Percentage of total plasma cells stained with anti-CD138 antibodies. 
B) Percentage of total isotype switched IgG1 (left hand side) and IgG2a/2b (right hand side) B cells. C) 
Percentage of MOG (left hand side) and OVA (right hand side) IgG1 binding B cells in RR and SJL/J WT mice. 
(SPL: spleen, mLNs: mesenteric lymph nodes, cLNs: cervical lymph nodes, LLNs: lumbar lymph nodes, BM: 
bone marrow). Data are representative of two independent experiments (n=3/group). 
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mice (data not shown). Although, B cell infiltrates were seen in both healthy and sick RR mice, 
isotype switched B cells were noted mainly in the CNS of sick RR mice and had only anti-MOG 
IgG1 isotype but not IgG2a/2b isotype (Figure 4.7C). Furthermore, amongst those infiltrating cells, 
there were negligible amount of plasma cells expressing CD138 detected by flow cytometric 
analysis (Figure 4.7C). Nevertheless, infiltrating CNS cells of sick mice showed a high 
production of anti-MOG IgG1 antibodies in culture, indicating that infiltrating B cells in the CNS 
are mature MOG-binding and isotyped switched antibody-producing cells (Figure 4.7D). 
4.1.4  Anti-MOG antibodies purification in RR mice 
As stated previously, mMOG monomers bound better to anti-MOG antibodies than to rMOG 
monomers, which allowed the use of reagent for anti-MOG antibodies clonality studies. Direct 
purification of anti-MOG antibodies from RR serum by passing antibodies through mMOG 
columns led to the loss of anti-MOG antibodies, which was largely of IgG1 isotype (Figure 4.8A). 
Figure 4.7. RR mice harbored Ig expressing B cells in the CNS. A) FACS plots showed gating protocol of 
infiltrating lymphocytes to the CNS. Lymphocyte population was gated from forward and side scatter plot, and 
infiltrating lymphocytes were distinguished from resident cells via high expression of CD45. B) Percentage of T 
and B cells in the CNS of RR mice. C) Percentage of CD138+, IgM+ and IgG1+ cells in the CNS of RR mice. D) 
MOG ELISA assay of CNS derived lymphocytes’ supernatant from RR and SJL/J WT mice cultured for 10 
days. Flow cytometric plots are representative of three independent experiments (n=2/group). ELISA assay is 


























































































This loss might be due to poor elution of high affinity anti-MOG antibodies or to loss in the flow 
through of the column (that contains serum anti-MOG antibodies) due to impurities of serum 
proteins. The loss of purified antibodies was solved by the introduction of protein G column to 
isolate all antibodies from other serum proteins (Figure 4.8A), which resulted in purified 
antibodies uncontaminated by other serum proteins as seen in SDS-PAGE gel (Figure 4.8C). 
However, despite the fact that protein G had recovered a high proportion of pure anti-MOG 
antibodies from RR crude serum, there was still some loss of anti-MOG antibodies (both IgG1 
and IgG2a) seen by the low OD values from purified anti-MOG antibodies compared to pooled 
serum before antibody purification in the MOG ELISA assay (Figure 4.8B).  
 
In order to find out how endogenously recruited B cell clonality will differ from induced humoral 
immunity, SJL/J WT mice were immunized with rMOG-alum and their serum was collected. 
rMOG-alum anti-MOG antibodies were purified, and these purified antibodies from RR mice and 
rMOG-alum immunized mice were separated on two-dimensional (2D) gels (Figure 4.8D).  
 
The 2D gels revealed strikingly increased antibody heterogeneity in RR mice than in rMOG-
alum immunized mice. Further experiments required to reduce antibody heterogeneity in RR 
Figure 4.8. Purification of serum anti-MOG antibodies. A) MOG ELISA shows that the purification of 
anti-MOG antibodies (IgG1, IgG2a) from RR mice directly through mMOG-conjugated column resulted in 
the loss of antibodies and was improved by enriching antibodies via protein G column. B) MOG ELISA 
assay of pooled serum anti-MOG antibodies from RR mice before and after purification. C) SDS-PAGE of 
purified serum antibodies from RR mice and rMOG-alum immunized mice (A: Protein G purified 
antibodies; B: purified antibodies from rMOG-alum immunized mice; C: purified antibodies from RR mice; 
M: molecular weight marker). D) 2D-gel shows anti-MOG antibodies from (a) RR mice and (b) rMOG-alum 
immunized mice, number of circles indicate the number of antibody clones. Data are representative of two 
independent experiments. 
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mice including de-glycosylation of purified antibodies, reduction in the number of mice to only 
one mouse and introduction of irrelevant intermediate protein (rOVA) to remove a polyclonal 
population, if there was any. However, firstly, the de-glycosylation step did not reduce much of 
anti-MOG heterogeneity from pooled RR mice’s serum (data not shown). Secondly, 2D gel was 
impossible to be performed due to the low amount of serum anti-MOG antibodies from a single 
RR mouse. However, purification of MOG-antibodies from RR-EAE (Figure 4.9A) and healthy 
mice (Figure 4.9B) had showed that healthy mice might have more free circulating and higher 
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Figure 4.9. Purification of anti-MOG antibodies from a single mouse. Mean fluorescence intensity (MFI) 
and histogram presentation of purified and concentrated anti-mMOG/rMOG antibodies from serum of RR 
mice (see Appendix 6.1 for detailed protocol 5b: eluted antibodies from mMOG conjugated column, 5a: flow 
through of mMOG/rMOG conjugated column, 3a: flow through of protein G column, 4a: flow through of 
irrelevant protein (rOVA), 4b: rOVA eluted antibodies). Graphs showed low levels of free anti-MOG antibodies 
from (A) sick mouse IgG1 with lower affinity as seen on the histogram compared to (B) healthy mouse serum. 
(EL4-MOG cells: dotted gray line and shadowed: EL4 cells: dotted black line; detection antibody only: dashed 




Therefore, antibodies deposited to CNS were purified. Brain and spinal cord were collected from 
22 RR-EAE mice with at least 1.5 of EAE severity scores, which had both anti-MOG IgG1 and 
IgG2a/2b isotypes in their serum as confirmed by MOG ELISA assay (Figure 4.10A). The purified 
concentrated antibodies from CNS were visualized by SDS-PAGE gel and detected by sliver 
staining. The gels showed pure and uncontaminated preparations of the RR-EAE CNS purified 
antibodies (Figure 4.10B). Figure 4.10 C and D prove that recovered antibodies were anti-MOG 
IgG1 antibodies when used to detect MOG protein by ELISA assay and antigen cell-bound 
assay on EL4-MOG cells. Despite those diseased mice had both IgG1 and IgG2a/2b antibodies in 
serum; only supposedly pathogenic IgG1 antibodies were recovered from CNS (Figure 4.10D). 
  
 
The limitation of the antibody quantity isolated from CNS and serum of a single mouse made it 
difficult to study the clonotypes of B cells in RR mice. Therefore, we decided to generate 
hybridomas to overcome the quantity problem. Unstimulated splenocytes from RR mice were 
fused with SP2/0 myeloma cell line. To test the specificity of grown hybridomas, supernatants 


















Figure 4.10. Isolation of MOG-specific antibodies from target tissue in RR mice. A) MOG ELISA assay 
of 22 RR mice’s serum showed that both anti-MOG Ig isotypes were detected (ns: non- statistically significant 
i.e. p-value >0.05). B) Silver staining of SDS-PAGE gel shows the heavy chains and light chains of tested 
antibodies and CNS purified antibodies (A: 8.18c5 positive control antibody; B: 1 µg and C: 10 µg of CNS 
purified antibodies; M: molecular weight marker). C) MOG ELISA assay shows that the purified antibodies 
were functional and detected MOG. D) Isolated IgG1 antibodies were MOG-specific and bond to 
conformational MOG expressed on EL4-MOG cells (EL4-MOG cells: dashed line, EL4 cells: black line, 
detection antibody only: dotted line, serum without detection antibody: gray line). Data are representative of 




were assayed against rMOG and rOVA as irrelevant antigens by ELISA assay. Although the 
generated hybridomas were still polyclonal, they all were specific to MOG (Figure 4.11B).  
Moreover, hybridoma produced antibodies were tested for their ability to bind to conformational 
MOG epitopes expressed by MOG-transfected EL4 cells (Figure 4.11A). Most anti-MOG 
hybridoma antibodies were of the IgG1 rather the IgG2a/2b isotype as seen in the MOG ELISA 
assay (Figure 4.11B, and data not shown). However, the mean fluorescence intensity (MFI) of 
anti-MOG antibodies indicated a binding affinity lower than of the standard anti-MOG 
monoclonal 8.18c5 (Figure 4.11A), but comparable to antibodies purified from serum and CNS 
of RR mice (Figure 4.10).  
 
These hybridomas provided the opportunity to study endogenous B cell populations via their 
antibody production without quantity problems as encountered via serum antibody purification 
and CNS antibody purification.  
  









Figure 4.11. Generation of RR splenocytes hybridomas. A) Mean fluorescence intensity (MFI) of 
antibodies purified from hybridomas via protein G columns compared to 8.18c5 (EL4-MOG: black line; EL4: 
gray line). B) rMOG (left hand side) and rOVA (right hand side) ELISA assay of four selected purified 




4.2  Summary of part 4.1 
Mammalian MOG tetramers (mMOGtet) were successfully utilized in RR mice to detect low 
frequency and low affinity MOG-binding B cells. MOG-binding B cells were broadly distributed 
through all lymphoid organs with tendency to accumulate in the CNS draining lymph nodes, and 
they are capable of producing anti-MOG antibodies. Anti-MOG IgG B cells were found in 
abundance in sick mice CNS. At least part of these antibodies seemed to be produced by CNS-
resident B cells because purified lymphocytes from CNS when cultured produced anti-MOG 
antibodies. 
MOG-specific antibodies were found to be heterogeneous in RR mice. RR mice start to produce 
MOG-specific antibodies from an early age (3 weeks) and continue to populate and develop 
throughout mice’s lifetime, which enabled B cells to evolve and become more heterogeneous 




4.3  Preclinical events of EAE development in RR mice 
4.3.1  Neural antigens drainage/ transport and deposition in CNS draining lymph nodes 
We hypothesized that capture of antigens from the CNS and their delivery to the nearest 
lymphoid organs is the first step in eliciting the B cells immune response in EAE. The constant 
export of these antigens to the CNS draining lymph nodes and epitope spreading might 
exacerbate the adaptive immune responses of both T and B cells that migrate back to the CNS 
resulting in an accumulation of damaging immune cells in the CNS. Therefore, studying these 
early events in spontaneous RR-EAE mice might help in elucidating the pathways by which 
antigens drainage or transport to the CNS draining lymph nodes occur.  
  
Direct immunohistochemistry staining of anti-neural antigens’ antibodies in the frozen section of 
lymphoid organs seemed to be a reasonable way to find myelin debris in CNS draining lymph 
nodes. In RR mice, myelin basic protein (MBP) was found within B cells compartment (Figure 
4.12A), while it was not found in SJL/J WT mice. Moreover, immunohistochemistry staining 
pattern in RR mice suggested that the proteolipid protein (PLP) was carried on the cell surface 
while MBP was within the cells (Figure 4.12B). However, one disadvantage of 
immunohistochemistry is non-specific staining mediated by the FC region of antibody that 
Figure 4.12. Deposition of neural antigens in RR mice. A) Fluorescent staining of cervical lymph node 
sections of RR and SJL/J WT mice for MBP (green) and B220+ B cells (in red). MBP deposition was seen in 
RR but not in SJL/J WT mice under 20x magnification. B) Fluorescent staining of RR mice cervical lymph 
node for PLP (red), MBP (green) and DAPI (blue), at 63x magnification to visualize that PLP was carried on 
the cell surface, while MBP appeared to be internalized. Data are representative of three independent 
experiments (n=2-3/group). 
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interacts with FC cell surface receptors. To circumvent this problem, we decided to produce 
myelin-specific antibodies lacking the FC region.  
 
 
We chose the anti-MOG monoclonal antibody Z2 for FC fragmentation for two reasons: firstly, 
because it largely replicates MBP staining pattern in lymphoid organs seen in RR mice and, 
secondly for the availability for MOG knockout (KO) RR mice as a negative control. The 
fragmentation of Z2 antibody into FC and fragment antigen-binding F(ab’)2 was completed 
(Figure 4.13A). After digesting the FC part of Z2 antibodies, it was important to test Z2 F(ab’)2 
capacity to detect MOG peptides on GPE cells (Figure 4.13B,C) and to stain MOG on spinal 
cord frozen sections (Figure 4.13D). Z2 F(ab’)2 stained GPE-MOG with lower MFI compared to 
8.18c5 and complete Z2 antibodies (Figure 4.13B). The Z2 F(ab’)2 staining for MOG in the MOG 
expressing spinal cord sections was optimal and absent in the spinal cord sections of MOG-KO 
RR mice (Figure 4.13C). Hence, Z2 F(ab’)2 was eligible to be used in the lymph nodes of RR 
mice to find out naturally deposited myelin protein and to control MOG staining in MOG 
knockout mice. Z2, Z2 F(ab’)2 and IgG2aκ isotype control antibodies were biotinylated, and equal 
Figure 4.13. Anti-MOG Z2 fragmentation to Z2 F(ab’)2. A) Silver stained native gel under non-reducing 
conditions showed Z2 fragmentation steps to F(ab’)2 (A: Z2 before digestion, B: washing step of fractionated 
Z2, C: after digestion, D: washing step after digestion, E: Z2 F(ab’)2 after dialysis, F: undigested Z2, M: 
molecular weight marker). B) Histogram showed Z2 F(ab’)2 (dashed line), Z2 (dotted line), 8.18c5 (black line) 
and secondary antibodies (gray color) when used to stain GPE-MOG and GPE cells. C) Quantification of 
mean fluorescence intensity (MFI) of anti-MOG antibodies Z2, 8.18c5, and Z2 F(ab’)2 that was shown in B. 
D) Immunohistochemistry staining of longitudinal sections of spinal cord taken from both RR and RR MOG-/- 
with anti-MOG antibodies 8.18c5, Z2 and Z2 F(ab’)2 (green) and DAPI (blue).  Pictures were taken at 
magnification 20x. Data are representative of at least two independent experiments.  





































amounts were used to perform immunohistochemistry staining in different lymphoid organs of 
RR and MOG-KO RR mice (Figure 4.14). The staining of lymphoid organs with anti-MOG 
Z2(Fab’)2 in RR and RR-MOG KO was negative; revealing what was thought to be specific 
staining by anti-myelin antibodies was, FC-mediated staining (Figure 4.14).  
 






























































Figure 4.14. Myelin deposition staining in lymph nodes was FC fragment mediated. Cryo-sections of 
selected lymph nodes (10 µm) from RR and RR MOG
-/- 
mice stained with B220
+
 (red) and anti-MOG antibodies 
Z2, F(ab’)2 fragment of Z2, as well as, IgG2a isotype control (green). Pictures were taken at magnification of 




Thus, these results necessitate a different myelin detection strategy and animal models, like 
introducing a fluorescent neural protein into the brain and tracing it back to lymph nodes to 
replicate CNS antigenic drainage or transportation. 
Experimental simulation of neural antigen drainage was performed by intrathecal injection (i.t) of 
mammalian MOG peptide conjugated to FITC (mMOG-FTIC) followed by a search for the 
fluorescent proteins. Fluorescence signals were detected in blood lymphocytes after 8 hours 
and 24 hours. The circulating fluorescence signals gradually decreased from the time of i.t. 
injection, 8 hours and 24 hours post i.t injection (Figure 4.15B). These FITC molecules in the 
blood were mainly carried by macrophages that expressed CD11b+ (data are not shown). In 
these mice, there were no lymphoid cells that invaded the brain and the spinal cord as indicated 
by the absence of CD45.1hi population (0.00%) in the CNS (Figure 4.18A). Injected mMOG-
FITC was mainly retained and engulfed by CNS microglia expressing CD45low CD11b+ (Figure 
4.15A), the remainder of FITC molecules was found in blood and cervical lymph nodes. Thus, in 
Figure 4.15. Cervical lymph nodes were the drainage site for intrathecally injected neural antigen. A) 
SJL/ J WT mice were intrathecally injected with 20 µg of mMOG only or mMOG conjugated with FITC, and 
organs were harvested after 24 hours for FACS analysis. FACS plots showed CD45low population from brain 
that was mainly CD11b (Microglia) carrying mMOG-FITC. B) Graph showing blood lymphocytes carrying 
mMOG-FITC after 8 and 24 hours. C) Drainage sites of i.t injected mMOG-FITC in different lymphoid organs 
(cLNs: cervical lymph nodes, LLNs: lumbar lymph nodes, aLNs, axillary lymph nodes, iLNs: inguinal lymph 
nodes, SPL: spleen, mLNs: mesenteric lymph nodes) (*p-value <0.05). Data are representative of two 






















line with previous studies (Weller et al., 2009) and (Carare et al., 2008), our experiments have 
confirmed that injected mMOG-FITC molecules end up in cervical lymph nodes (Figure 4.15C).  
 
Furthermore, we used PLP-eGFP mice (C57BL/6 mice with part of the PLP is fused with GFP) 
to characterize the transport of myelin antigen to the periphery (Figure 4.16). PLP-eGFP mice 
were immunized and sacrificed at the peak of the disease in order to find any fluorescent 
signals in lymphoid organs that might indicate PLP drainage from CNS to lymphoid organs. 
Blood lymphocytes and monocytes were, in fact, the only site where PLP could be detected, 
however, no eGFP positive cells seen in any of the lymph nodes (Figure 4.16D,E). It is possible 
Figure 4.16. Neural antigens were carried by blood cells in eGFP-PLP mice. A) Gating protocol to 
identify GFP positive cells from blood cells. Example of flow cytometric plots showed which cells were 
carrying eGFP comparing PLP-eGFP C57BL6 mice to immunized WT C57BL/6 mice in B) blood lymphocytes 
population and C) monocytes population. D) Quantification of total eGFP-PLP in blood cells and E) in 
different lymphoid organs (aLNs: axillary lymph nodes, iLNs: inguinal lymph nodes, cLNs: cervical lymph 
nodes, LLNs: lumbar lymph nodes, mLNs: mesenteric lymph nodes, SPL: spleen, BM: bone marrow). Data 




































































that eGFP might have been digested immediately after uptake by phagocytes before they have 
reached any lymphoid organs.  
 
4.3.2  Preclinical infiltration of immune cells in the CNS 
Early activation of B cells can occur in the peripheral lymphoid organs after drainage of neural 
antigens, or in the CNS after immigration of peripheral immune cells. In either case, anti-MOG 
antibodies could be used as a marker for pre-clinical immune cell activation because it is easy 
to non-invasively monitor in blood and anti-MOG antibodies production in RR mice starts very 
early in mice’s lifetime (4 weeks), well before any EAE disease symptoms appear. Lymphocyte 
infiltration in the CNS was followed by three means: gene expression, immunohistochemistry 
staining and flow cytometric analysis before and after first sign of anti-MOG antibodies 
production in RR mice-that is before and after 4 weeks of mice-age-.   
  
Gene expression analyses of CD19+ B cells and transgenic T cell receptor genes (Vβ4 and 
Vα8.3) of 3 and 6 weeks old RR mice indicated an early infiltration of T and B lymphocytes 
(Figure 4.17). Different CNS regions showed different numbers of infiltrating T and B cells and 
were most evident at 6 weeks old mice or later (Figure 4.17, 4.18, 4.19 and data not shown). In 
the brain, cerebellum and brainstem contained more lymphocytes infiltrates than other regions 
(data not shown); similarly the lumbar spinal cord had more infiltrates than upper regions of 
A 
B 
Figure 4.17. Preclinical infiltration of lymphocytes in RR mice. Brain tissue (cerebral cortex) from 3 and 6 
weeks RR mice showed an early infiltration of A) T cells indicated by their transgenic chains (Vβ4 and Vα8.3), 
and B) B cells infiltration seen by gene expression of CD19 in relative expression to housekeeping gene 
GAPDH. Data are representative of two independent experiments (n=2-4/group). 
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spinal cord. B cells might have been recruited later to the CNS than T cells, as suggested by 
low expression of CD19 cell marker of B cells in 3 weeks old RR mice compared to 6 weeks old 
mice (Figure 4.17B), implying that T cells are the pioneer infiltrates to the target tissue opening 
the door for B cells to follow them to residue and populate in the CNS.  
Early lymphocyte infiltration was also demonstrated by immunohistochemistry staining, mainly in 
RR mice (Figure 4.18). In the CNS of 2 weeks old RR mice, there were few scattered T cells in 
the cerebellum or brain stem and B cells were completely absent (Figure 4.18). However, in 6 
weeks old mice, infiltration of T and B cells were detected easily, with T cells homing alone or in 
cluster while B cells were only found in aggregates together with T cells (Figure 4.18). Finally, 
from the previous experiments, it was observed that CNS infiltrates found in different quantities 
and accumulation preferably, in the cerebellum and brain stem in the brain and lumbar section 
of the spinal cord with T cells being the pioneer infiltrates. 
  
 
Finally, anti-MOG antibodies can indicate an immune reaction against MOG in RR mice even 
before the onset of clinical symptoms and their detection in serum at early age provides an 
opportunity to study and correlate the initial immune events preceding the development of 
clinical disease.  
Two weeks old RR mice had few lymphocyte infiltrates in the CNS (≤ 2000 infiltrating T cells) 
(Figure 4.19). At this very young age, the mice did not develop any anti-MOG antibodies both in 
blood serum and ex vivo organ culture´s supernatant (Figure 4.21). Collectively, at 2 weeks of 
mice-age, data suggested that APCs including B cells did not meet their cognate antigens yet to 
produce antibodies.  
Figure 4.18. Preclinical infiltration of lymphocytes to the CNS in RR mice. Cryosections of brain (10 µm) 
from RR mice showed B cells (B220) in red, T cells (CD4) in green and DAPI in blue. Pictures were taken 
from the brain stem of 2 weeks old mice (right hand side), and the cerebellum of 6 weeks old mouse (left 
hand side). Pictures were taken at 20x magnification (zoomed in at the top right hand corner). Data are 
representative of independent three experiments (n=3-4/group). 
B cells T cells DAPI B cells T cells DAPI 
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Four weeks old RR mice had a higher number of T cells infiltrating the CNS but still few B cells 
(≅2000) (Figure 4.19). The B cells at the periphery, however, showed immuno-activation 
reflected by the production of anti-MOG antibodies IgG1 in the serum and also by ex vivo single 
organ culture, with the highest anti-MOG antibodies production in the cervical lymph nodes 
(Figure 4.21). The number of infiltrating lymphocytes did not show any correlation with anti-
MOG IgG1 and IgG2a/2b antibodies seen by linear regression analysis (table 4.1). From our i.t 
injection experiments and the literature (Carare et al., 2008), we learned that antigen release is 
















B cells T cells 
Figure 4.19. Preclinical infiltration of T and B lymphocytes in relation to anti-MOG serum antibody 
production. FACS beads were used to count infiltrating T and B cells in the CNS from RR and SJL/J WT 
mice at different ages, and blood serum was collected. Serum MOG ELISA readings (X-axis) and the number 
of infiltrating cells (Y-axis) were plotted into XY graph and on X-axis there is a red dashed line indicates 
baseline infiltration (≅2000 cells). Data are pooled from two independent experiments (n=4-6/group). 
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assumed that antigen release and capture was before the production of anti-MOG antibodies 
leading to T and B cells infiltration to the CNS, sometimes between week 2 and week 4 (Figure 
4. 19, .21).  
 
Finally, at 6 weeks of mice-age, autoimmune reactivity was amplified in the brain with an 
increased number of both T and B cells infiltrating the CNS (Figure 4.19). Ex vivo organ cultures 
of these 6 weeks old mice produced a higher amount of anti-MOG antibodies compared to 
younger mice with those from cervical lymph nodes being the highest and most persistent 
(Figure 4.21). At 6 weeks of mice-age, the immune system had reached a balance having tight 
correlation between infiltrating T and B cells in the CNS to anti-MOG antibodies in mice serum 
in the periphery (Figure 4. 19 and Table 4.1). Interestingly, the strongest correlation was seen 
with serum anti-MOG IgG1 antibodies which are believed to be pathogenic with B cells infiltration 
of value equal to R2=0.77, followed by anti-MOG IgG1 antibodies with T cells infiltration 
(R2=0.65) as tested using linear regression analysis (Table 4.1). 
Table 4.1. Lymphocytes infiltrated to the RR mice CNS correlates with its serum. Regression values 
(R
2
) of the absolute number of infiltrated lymphocytes (T and B cells) to the CNS compared to anti-MOG IgG1 
and IgG2a/2b antibodies from blood serum of RR mice at age of 4 and 6 weeks. Data are pooled from two 
independent experiments (n=4-6/group) presented in Figure 4.19. 
4 weeks 6 weeks 
IgG1 IgG2a/2b IgG1 IgG2a/2b 
T cells 0.3162 0.3542 0.6471 0.3453 
B cells 0.0997 0.0311 0.7727 0.4670 
Figure 4.20. Pre-clinical infiltration of mainly T memory lymphocytes. FACS beads were used to count 
the absolute number of infiltrating T cells in the CNS from RR mice at different ages. Absolute number of low 
and high TCR chains Vβ4 and Vα8.3 expressing T cells (memory, naive phenotype respectively) were 














Moreover, infiltrating T cells to the CNS were mainly expressing a memory phenotype and 
gradually built up in the CNS with age (Figure 4.20). However, in 6 weeks old mice, we 
observed a sudden increase in absolute numbers of naïve infiltrating T cells in the CNS, which 
might suggest that the lymphocytes had found a niche in the site of inflammation to divide and 
proliferate (Figure 4.21) or simply BBB was “open” for more naive T cells to arrive at the CNS. 
 
Figure 4.21. Cervical lymph nodes contributed the most to the serum anti-MOG antibodies in RR mice. 
Whole organs were cultured from RR mice at different ages (cLNs: cervical lymph nodes, aLNs: axillary 
lymph nodes, iLNs: inguinal lymph nodes, LLNs: lumbar lymph nodes, mLNs: mesenteric lymph nodes, SPL: 
spleen, BM: bone marrow). Supernatant of organs’ culture and serum were used to stain EL4-MOG cells, and 
mean fluorescence intensity (MFI) was calculated. Data representative of two independent experiments (n=2-
3/group). 


















4.4  Summary of part 4.3 
RR mouse model is a unique, spontaneous model, where the preclinical stage of the disease 
seems to be relatively long allowing for studying preclinical immune events. It was learnt that 
neural antigens are drained to CNS lymphoid organs. Signs of pre-clinical events of EAE were –
here- simplified by increased absolute number of lymphocytes in the CNS and systemic anti-
MOG antibodies production. At 4 weeks of mice-age, lymphocytes were peripherally recruited, 
evident by anti-MOG antibodies production and slightly exceeding baseline infiltration of T cells 
to the CNS. At 6 weeks of mice-age, peripheral reaction seemed to be tailored to fit the 
inflammation demands in the CNS as seen by the correlation between anti-MOG antibodies 
and, the absolute number of both infiltrating T and B lymphocytes to the CNS. This correlation 





CHAPTER 5: DISCUSSION 
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5.  Discussion 
5.1  MOG-binding B cells in CNS drainage lymph nodes 
B cells express surface immunoglobulin (sIg) molecules as antigen binding receptors and each 
B cell expresses sIg with a single antigen binding specificity (Buisman et al., 2009). The 
identification of antigen-specific B is a challenging task, because in the entire immune repertoire 
the frequency of cells specific for any particular antigen is usually less than 1% (Scheid et al., 
2009, Wu et al., 2010). 
Tetramer technology, as introduced by Altman et al. (1996), has become widespread in 
identifying antigen specific lymphocyte clones. As a method to identify and phenotypically 
characterize Ag-specific T lymphocytes, it has quickly advanced our understanding of the 
immune response from a general sense to a more precise sense. This technology is mainly 
used in flow cytometry to quantify ex vivo antigen-specific T cells by binding soluble tetramer 
MHC-peptide complexes attached to a fluorochrome (Vollers and Stern, 2008). Quantitative 
analyses of antigen-specific immune cell populations provided valuable information on the 
natural course of immune responses, such as in viral, bacterial, or parasitic infections, cancer, 
autoimmune diseases and transplantation. However, this technology has been used less in B 
cells (Gieseke et al., 2012). We applied tetramer technology to study autoimmune B cells in RR 
mice, where anti-MOG antibodies are seen from 3-4 weeks of mice-age, and which are 
produced by a few thousands of antigen-specific B cells. Detection of MOG-binding B cells was 
hampered by their low affinity and low frequency. Therefore, we expressed MOG peptide 1-125 
in HEK EBNA eukaryotic cells, allowing for glycosylation, to keep correct conformational 
structure, and oligomerized the protein in analogy to MHC tetramers. Therefore, MOG 
tetramerization technique allowed detecting mMOG-binding B cells in RR mice especially in 
CNS draining lymph nodes.  
It is well established that the high-affinity binding of autoantibodies to self-antigens is critical for 
their pathogenic activity in autoimmune disease in vivo (Shlomchik et al., 1987). This concept 
has been supported by the demonstration that autoimmune Ig genes, which were clonally 
expanded, were modified by somatic mutations in GC (Shlomchik et al., 1987). Further support 
of affinity maturation came from the observation that IgM to IgG class switching coincided with 
progression of the clinical development of autoimmune diseases, such as in SLE (Tillman et al., 
1992, Hirose et al., 1993). However, in RR mice most of the purified antibodies were of low 
affinity as compared to a classical MOG binding mAb (8.18c5) used as a positive control. 
Therefore, two points needed to be clarified: Firstly, affinity maturation of autoantibodies in 
parallel to Ig class switching and somatic hypermutations were not consistently observed. These 
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results were similar to a study of clonally related anti-IgG2a rheumatoid factors from a lupus-
prone MRL-lpr/lpr mouse, which had demonstrated limited affinity maturation, despite Ig isotype 
switching with extensive somatic mutations (Jacobson et al., 1994). During our experiments, we 
also noted that in the RR mice EAE incidence did not dictate isotype switching or affinity 
maturation that is IgG1 and IgG2a/2b switching was not shaped by the disease course. Secondly, 
studies of rheumatoid factor monoclonal autoantibodies disclosed that low-affinity 
autoantibodies are able to induce immune complex–mediated vasculitis (Berney et al., 1992, 
Fulpius et al., 1993). Also low affinity IgG anti–mouse RBC monoclonal autoantibodies had a 
significant role of FcγR-mediated erythrophagocytosis in the development of anemia (Clynes 
and Ravetch, 1995). Thus, it was speculated that low-affinity B cells could become highly 
pathogenic (Fossati-Jimack et al., 1999), and are also driven to germinal center formation (Dal 
Porto et al., 1998). The same was observed in this study where, mMOGtet allowed visualizing 
low affinity MOG-binding B cells within the germinal center, which was not possible to be 
detected by rMOG. Moreover, about 40% of normal adult B cell population are polyreactive and 
are the predominant cell type in the newborn up to 90% (Chen et al., 1998). The B1 subset is 
believed to be the main population producing polyreactive antibodies (Kantor et al., 1995, Hardy 
et al., 1994). Unlike what we found in RR mice, hybridomas were polyclonal monoreactive to 
MOG. 
 
5.2  MOG-binding B cells in the CNS of RR mice 
B cells are known to enter CNS during normal immune surveillance and in disease (Alter et al., 
2003). In RR mice, there are more T cells than B cells infiltrated into the CNS. Most of the CNS 
infiltrating B cells in RR mice were capable of producing anti-MOG antibodies of the IgG1 
isotype. The switch to IgG1 takes place in germinal centers and requires the presence of T cells 
and autoantigen. How and where would T cell, B cells and autoantigen meet? One possibility is 
indicated by Cserr and Berman (1978), who have developed a system in which a fine cannula 
placed in the brain parenchyma is left in place while the BBB becomes reestablished. Their 
system allowed infusing minute amounts of an antigen directly into the CNS without 
traumatically disrupting the reconstituted BBB. When antigens were introduced behind the 
reconstituted BBB, antigen-specific B lymphocytes and plasma cells accumulate near the tip of 
the cannula. This observation suggested that activated B lymphoblasts can circulate and pass 
through CNS tissues in search of their antigens as was observed in early infiltration of B cells in 
RR mice, and they have populated there.  
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Antibodies of limited clonality (oligoclonal bands) are found in the CNS and cerebrospinal fluid 
(CSF) of patients with MS (Kabat et al., 1942). Clonally expanded CNS resident B cells are 
partially accountable for the emergence of these oligoclonal bands, stressing the importance of 
B cells for development or course of MS (Obermeier et al., 2008). In RR mice, Ig deposition is 
evident in the CNS (Pollinger et al., 2009). Deposited Ig in RR mice was MOG-specific and IgG1 
isotype. Despite the fact that these mice were capable of producing both anti-MOG IgG1 and 
IgG2a/2b isotypes, CNS dissociated anti-MOG antibodies of sick RR mice did not show much 
IgG2a isotype. The aforesaid result might be attributed either to low numbers of isotype switched 
B cells to IgG2a/2b in the CNS or due to high adhesive capacity of IgG2a antibodies, as mentioned 
in several studies (Hazenbos et al., 1996). In vitro, it had been shown that murine IgG1 and 
IgG2b interacted preferentially with the low affinity receptors, FcγRIIB and FcγRIII, and IgG2a with 
the high affinity receptor, FcγRI (Hazenbos et al., 1996). More recently, Nimmerjahn et al. 
(2005) had shown that FcγRIV bound to IgG2a and IgG2b with at least 10-fold higher affinity than 
FcγRIII, but it did not bind to IgG1 with measurable affinity.  
 
5.3  RR mice hybridoma to study anti-MOG antibody clones 
We agreed with Zhou et al, 2007 that in analyses of antibody and B cell repertoires, the best 
way to overcome the low quantity of antibodies ex vivo is to create hybridomas from RR mice. 
MOG-specific antibodies from blood serum recovered less than a few nanograms per ml (data 
not shown) after extended processing for a single RR mouse (Appendix 6.1) and the 
heterogeneity of these preparations were also vast. 
Hybridomas from normal mice commonly produce polyreactive antibodies that reacted with 
normal tissues (Coutinho et al., 1995, Dighiero et al., 1983). However, in RR mice it was not the 
case, RR mice’s hybridomas were polyclonal yet monoreactive to MOG. Antigen specificity was 
determined by ELISA with two antigens rMOG and rOVA, which was amongst the panel of 
antigens tested by others (Coutinho et al., 1995, Dighiero et al., 1983). Furthermore, our studies 
using ELISA and FACS proved that RR-hybridomas generated from RR spleen are 
monoreactive to both linear and conformational MOG epitopes. 
Additionally, the affinity of created hybridomas was lower than the anti-MOG antibody 8.18c5. It 
was, however, comparable to anti-MOG antibodies from RR mice’s serum and the extracted 
from the CNS tissue. It should be noted that the anti-MOG 8.18c5 was created from an 
immunized mouse while RR hybridomas were derived from naturally and endogenously 
recruited autoimmune B cells. As stated earlier, low affinity binding antibodies are not 
necessarily less pathogenic (Fossati-Jimack et al., 1999). In general, we are aware that these 
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results are very preliminary and just a baseline towards the approach of analyzing clonality of 
RR B cells in both lymph nodes and CNS. Unfortunately, limited genetic database resources of 
SJL/J mouse background have also, hindered the study.  
 
5.4  Neural antigen transportation 
Besides immune cell infiltrates in the CNS, CNS draining lymph nodes such as cervical lymph 
nodes are a possible meeting place for anti-MOG T and B cells. Indeed, transferred IgHMOG B 
cells preferentially homed to the cervical lymph nodes of RR mice (Berer et al., 2011a). But this 
would require the presence of MOG in these lymph nodes. There are two separate pathways for 
neural antigen drainage to cervical lymph nodes, via interstitial fluid (ISF) and cerebral spinal 
fluid (CSF). ISF and solutes drain from the brain along the 100-150 nm wide basement 
membranes of the walls of the capillaries and arteries (Carare et al., 2008). The failure of APCs 
to migrate to lymph nodes along perivascular lymphatic draining pathways may be a significant 
factor in immunological privilege of the brain (Weller et al., 2009). Lymphatic drainage of CSF is 
predominantly through the cribriform plate into nasal lymphatics (Weller et al., 2009). Several 
studies have shown that there is antigen drainage in MS and EAE to CNS draining lymphoid 
organs. Antigen drainage has been shown via PLP detection and different anti-myelin 
antibodies in cervical lymph nodes. Also, surgically removal of cervical lymph nodes where 
antigen drains reduced the severity of EAE (Zwam et al., 2009). Using similar methods such as 
staining for myelin antigen in the CNS draining lymph nodes we also saw MBP and PLP-like 
material in cervical lymph nodes of RR mice. Unfortunately, further examining this technique by 
introducing an antigen-deficient animal control has shown anti-MOG antibodies staining in 
cryosections can be seen in both RR and RR MOG KO mice cervical lymph nodes, implying that 
the positive staining is most likely to be mediated by unspecific antibody binding to Fc-receptors 
(Leong, 2004, Holmseth et al., 2006, Fritschy, 2008, Daneshtalab et al., 2010). Still, intrathecal 
injection of different markers has revealed that antigens drain to cervical lymph nodes (Carare 
et al., 2008), as was seen by soluble tracers (dextran) draining along the basement membranes 
of capillaries and arteries in naive mouse brains only 5 minutes after intrathecal injection 
(Carare et al., 2008). Our study showed that within 8 hours after intrathecal injection of mMOG-
FITC, FITC was detected in blood lymphocytes and monocytes. Mathematical modeling 
suggested that contrary waves drive drainage of interstitial fluid, solutes, and neural antigens 
away from the brain in reverse perivascular transport, but not perivascular macrophages 
(Schley et al., 2006). Important to note, intrathecal injection did stimulate infiltration of any 
CD45hi lymphocytes populations or release of CD45low from CNS as seen in EAE in eGFP-PLP 
Discussion 
58 
mice, which indicated that infiltration of CD45hi population was a consequence of antigen 
drainage, not a cause.  
 
5.5  Preclinical infiltration of lymphocytes 
Both transgenic T cells and endogenously recruited B cells infiltrated the CNS from a young age 
in RR mice. Infiltrated cells were seen mainly in the cerebellum and brain stem of RR mice and 
in the lumbar section of spinal cord. The first wave of infiltrating lymphocytes was seen by 4 
weeks, paralleled by increased anti-MOG antibodies production in the cervical lymph nodes. A 
similar experiment was performed by Furtado et al, 2008 where in myelin basic protein (MBP)-
specific TCR transgenic mice spontaneous disease onset and CNS infiltration of T cells 
coincided with, priming of T cells in the cervical lymph node and their activation via expression 
of CD69 and CD44 by the age of 6 weeks. In RR mice, by 6 weeks of age, priming of the 
immune system was checked by anti-MOG antibodies serum titer detection and it was 
correlated with the amount of infiltrated T and B cells to the CNS. The number of lymphocytes 
infiltrating the CNS along with MOG-specific serum antibodies might determine which mice were 
going to remain healthy or become sick. It may take longer to develop EAE by reduced anti-
MOG antibodies titer in serum as compared to mice with increased anti-MOG serum titer. This 
correlation between disease severity and serum titer was also observed in rheumatoid arthritis 
(Cambridge et al., 2003). Finally, it has shown that infiltrating T cells to the CNS express 
memory phenotypes at the peak of EAE (Giunti et al., 2003). In RR mice, however, T cells 
infiltrating into the CNS have memory phenotype indicated by reduced TCR chain expression 
from a very young mice and increases gradually with age, which might suggest that T cells have 
found a niche to populate or memory phenotype is required to enter to CNS.
 59 
CHAPTER 6: CONCLUSION  
Conclusion 
60 
6.  Conclusion 
Mammalian MOG tetramer was successfully utilized in RR mice to detect low frequency and low 
affinity MOG-binding B cells. MOG-binding B cells were vastly distributed in all lymphoid organs 
in RR mice with the tendency to accumulate in the CNS draining lymph nodes. MOG-specific 
antibodies were found to be heterogeneous in RR mice as it evolves from a very young age. 
Furthermore, neural antigen drainage to lymphoid organs is immediate and neither requires 
cells of myeloid origin to leave the CNS nor infiltrating cells from the periphery to carry them out 
of CNS. Signs of pre-clinical events of EAE were –here- simplified by increased absolute 
number of lymphocytes in the CNS and systemic anti-MOG antibodies production. At 6 weeks 
old mice, anti-MOG antibody serum titer correlated with the absolute number of both B cells and 
T lymphocytes infiltrating to the CNS, which might potentially suggest which of RR mice will 
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